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Abstract 
 
Background: Many well-known pharmacologic agents have been shown to have toxic effects 
to the cochleo-vestibular system. Examples of such ototoxic agents include cisplatin and 
aminoglycoside antibiotics. Ototoxicity monitoring consists of a comprehensive pattern of 
audiological assessments designed to detect the onset of any hearing loss. Three main 
methods have emerged over the past decade, and include the basic audiological assessment, 
extended high frequency (EHF) audiometry, and otoacoustic emission (OAE) measurement.  
These measures can be used separately or in combination, depending on clinical purpose and 
patient considerations.  It is suggested by the American Academy of Audiology Position 
Statement and Clinical Practice Guidelines: Ototoxicity Monitoring, that baseline testing be 
done in a fairly comprehensive manner, including pure-tone thresholds in both the 
conventional- and extended high frequency ranges, tympanometry, speech audiometry, and 
the testing of OAEs (AAA, 2009).  Anecdotal evidence suggests that New Zealand 
Audiologists do not currently follow a national ototoxicity monitoring protocol. Therefore the 
main aim of this study was to explore the current status of ototoxicity monitoring within New 
Zealand. 
Hypothesis: It was hypothesized that hospital based Audiology departments across New 
Zealand each followed their own internal ototoxicity monitoring protocol based, to a large 
extent, on the guidelines proposed by the American Academy of Audiology and by the 
American Speech-Language-Hearing Association.  
Method: Through the use of a Telephone Interview Questionnaire, 16 charge Audiologists 
were interviewed to establish their current state of knowledge regarding ototoxicity 
monitoring at 16 out of 20 district health boards in New Zealand.  Enquiries about the current 
systems and procedures in place at their departments together with any suggestions and 
recommendations to improve on these systems were made. 
Results: This study found that only 9 of the 16 DHBs interviewed currently follow an 
ototoxicity monitoring protocol. Furthermore, other than initially hypothesized the origin of 
the protocols followed by the remaining 7 departments were reported to have ranged from 
independently developed protocols to historically adopted protocols. One department 
implemented an adapted version of a protocol by Fausti et al. (Ear and Hearing 1999; 
20(6):497-505). This diversity in origin however, does confirm our initial suspicion that no 
universal and standardized monitoring protocol is currently being followed by Audiologists 
working in the public health sector of New Zealand. 
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1 Introduction 
1.1 Ototoxicity and its causes 
Ototoxicity is defined as the tendency of certain therapeutic agents to cause functional 
impairment and cellular degeneration of the inner ear and the eighth cranial nerve 
(Figure 1)  (Govaerts, et al., 1990).  
 
 
Figure 1. Anatomy of the human ear. 
 
The propensity of specific classes of drugs to cause ototoxicity has been well 
established, and over 130 drugs have so far been associated with ototoxicity (Canalis 
& Lambert, 2000). The best documented of these include aminoglycoside antibiotics 
such as streptomycin and kanamycin, loop diuretics such as furosemide, and the 
antineoplastic agent cisplatin (Schacht & Hawkins, 2005). 
That some medicines can affect hearing has been known for centuries (Stephens, 
1982). In the first half of the 20
th
 century, the arsenical compound Salvarsan 
(arsphenamine) was used to treat syphilis, with ototoxic side-effects.  However, it was 
not until the 1944 discovery of streptomycin - an antibiotic that promised to eradicate 
infectious diseases - that the problem of ototoxicity achieved wide public awareness. 
At the time streptomycin was used successfully in the treatment of tuberculosis. Only 
one year after the discovery of streptomycin, the side effects against the inner ear and 
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the kidney were apparent (Schacht & Hawkins, 2005). A substantial number of treated 
patients were also found to have developed irreversible cochlear and vestibular 
dysfunction (Kahlmeter & Dahlager, 1984). These findings, coupled with ototoxicity 
associated with later development of other aminoglycosides (such as the highly 
ototoxic kanamycin and amikacin),  led to a great deal of clinical and basic scientific 
research into the aetiology and mechanisms of ototoxicity (Fowler, 1948; Schacht & 
Hawkins, 2006).  
Ototoxicity has typically been shown to be associated with bilateral high-frequency 
sensorineural hearing loss and tinnitus (Crepaldi, Umeoka, Viera, & de Moraes, 
2008). Hearing loss can be temporary but is usually irreversible with most agents 
(Roland, 2004). Additionally, hearing loss may not manifest until several weeks or 
months after completion of antibiotic or antineoplastic therapy (Li, Womer, & Silber, 
2004). 
 
Table 1.  Degrees of hearing loss (Jerger & Jerger, 1980). 
 
Range of dB HL Classification 
-10 to 20 dB HL 
  21 to 40 dB HL 
  41 to 55 dB HL 
  56 to 70 dB HL 
  71 to 90 dB HL 
  91+ dB HL 
Normal hearing 
Mild hearing loss 
Moderate hearing loss 
Moderately-severe hearing loss 
Severe hearing loss 
Profound hearing loss 
 
Permanent hearing loss or balance disorders caused by ototoxic drugs may have 
serious communication, educational, and social consequences (Knight, Kraemer, & 
Neuwelt, 2005). Therefore, the benefits of ototoxic drugs must be weighed against the 
potential risks, and alternative medications should be considered when appropriate. 
The emphasis is on prevention, as most hearing loss is irreversible. Although there are 
currently no therapies available to reverse ototoxic damage, scientists and clinicians 
continually seek new methods to minimize ototoxic injury while preserving the 
therapeutic efficacy of these drugs.  
Ototoxicity for pure-tone thresholds between 500 Hz and 16 kHz is defined by the 
American Speech- Language- Hearing Association as a 20 dB or greater decrease in 
pure-tone threshold at a single test frequency, a 10 dB or greater decrease in threshold 
at two adjacent frequencies, or loss of response at three consecutive frequencies where 
responses were previously obtained (ASHA, 1994). 
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Clinical studies have demonstrated an irreversible ototoxicity incidence ranging from 
9% to 91% depending on the criteria used and the cumulative dose (Blakley & Myers, 
1993; Montaguti, et al., 2002). Symptoms are frequently present at the onset of 
measurable hearing loss. Risk factors for ototoxicity include renal insufficiency, 
intravenous bolus delivery, co-administration with aminoglycosides, and increased 
cumulative doses. Today, many well-known pharmacologic agents have been shown 
to have toxic effects to the cochleo-vestibular system (Table 2). One such agent is 
cisplatin - a platinum-based antineoplastic. 
 
Table 2. Common substances known to be associated with ototoxicity. 
 
Type/group Name of ototoxic substance 
Aminoglycoside antibiotics Gentamicin, streptomycin, tobramycin, 
neomycin, netilimicin, kanamycin, 
amkicacin, dihydrostreptomycin, 
ribostamycin 
 
Non-aminoglycoside antibiotics Vancomycin, erythromycin 
 
Loop diuretics Furosemide, ethacrynic acid, bumetanide, 
torsemide 
 
Chemotherapeutic agents Cisplatin, carboplatin, nitrogen mustard 
 
Salicylates Aspirin 
 
Anti-malarial drugs Quinine, chloroquine 
 
Environmental chemicals and other 
substances 
Lead, mercury, carbon monoxide, arsenic, 
carbon disulfide, tin, hexane, toluene, 
alcohol 
 
1.2 Cisplatin 
Cisplatin is a platinum based compound (Figure 2) and is one of the most potent 
cytotoxic drugs currently available to treat different types of cancer including 
medulloblastoma, neuroblastoma, osteosarcoma, and cancers of the testes, ovaries, 
cervix, bladder, lung, and head and neck (Rybak & Whitworth, 2005). 
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Figure 2. A 3D model of the cisplatin structure (Harrison, 2005). 
 
Cisplatin‟s antitumor properties can be attributed to its chloride ligand displacement 
reactions which ultimately lead to DNA cross linking, and can be seen in (Figure 3).  
 
Figure 3. DNA adduct formation with cisplatin leaving two amino groups coordinated on the 
platinum atom (Boulikas, 2007). 
 
Cisplatin-induced ototoxicity has been shown to occur in between 3% (Forastiere, 
Takasugi, Baker, Wolf, & Kudla-Hatch, 1987) and 100% of patients (Kopelman, 
Budnick, Sessions, Kramer, & Wong, 1988). In another study, however, elevated 
hearing thresholds were demonstrated in 75-100% of patients treated with cisplatin 
(McKeage, 1995). Ototoxicity is one of a number of severe side effects which limit 
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the clinical efficacy of cisplatin. Others include nephro-, neuro-, and gastro-toxicity 
(Rademaker-Lakhai, et al., 2006). Of these side effects, peripheral neurotoxicity and 
ototoxicity are potentially the major dose-limiting factors, in that they are cumulative 
and in general only partially reversible with discontinuation of therapy (Hill, Morest, 
& Parham, 2008).  
Cisplatin-induced ototoxicity generally manifests as tinnitus and sensorineural hearing 
loss (Van der Hulst, Dreschler, & Urbanus, 1988). This hearing loss is dose related, 
cumulative, bilateral, and usually permanent and has been reported to occur at high 
frequencies (Roland, 2004). Other than higher dosage and longer duration of cisplatin 
therapy, the risk factors useful for predicting the risk of ototoxicity remain 
undetermined (Rademaker-Lakhai, et al., 2006).  
Previous studies have shown that cisplatin results in the loss of outer hair cells 
(OHCs) specifically (Figure 4 and Figure 5), and that the loss of hair cells starts at 
the base of the cochlea (Nakai, et al., 1982).  
 
Figure 4. Normal OHCs in the basal portion of the cochlea, with their orderly arrangement of 
stereocilia (Kasse, et al., 2008). 
 
 
Figure 5. Extensive OHC injury in the basal portion of the cochlea due to cisplatin treatment 
(Kasse, et al., 2008). 
 
In addition to the OHCs, it is suggested that the marginal cells of the stria vascularis 
and fibrocytes of the spiral ligament are also injured (Van Ruijven, De Groot, Klis, & 
Smoorenburg, 2005).  
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1.3 Aminoglycosides 
As mentioned before, the discovery of the aminoglycoside antibiotics in the 1940s 
were the long-sought remedy for tuberculosis and other serious bacterial infections in 
developing countries (Wu, Sha, & Schacht, 2000). Commonly used aminoglycosides 
include amikacin, gentamicin, and tobramycin (Li, et al., 2004). They exhibit 
antimicrobial activity against a wide spectrum of different micro-organisms, including 
Gram-negative and Gram-positive bacteria, mycobacterium and protozoa (Durante-
Mangoni, Grammatikos, Utili, & Falagas, 2009). The most frequently prescribed 
molecules are gentamicin, tobramycin an amikacin. Aminoglycosides exert their 
activity by binding to the aminoacyl site of 16S ribosomal RNA within the 30S 
ribosomal subunit (Fourmy, Recht, Blanchard, & Puglisi, 1996). The mechanism of 
action thus involves penetration within the target cell and direct interference with 
bacterial protein synthesis. 
 
 
Figure 6. Molecular structure of Gentamicin ("Pharmaceutical Press," 2006).  
 
These drugs are usually administered intravenously in two to four doses a day in 
patients with normal renal function (Barza, Ioannidis, Cappelleri, & Lau, 1996). The 
major adverse effects of these drugs are dose-dependent nephro- and ototoxicity, with 
impairment of both hearing and vestibular functions (Durante-Mangoni, et al., 2009). 
Approximately 15-20% of patients receiving aminoglycosides experience significant 
hearing loss and/or balance disorders (Taleb, et al., 2009). Hypersensitivity reactions, 
nausea, vomiting, headache, tremor, arthralgia (joint pain) and hypotension have also 
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been reported (Wu, et al., 2000). Experimental evidence accumulated over the last 
decade has left little doubt that reactive oxygen species (ROS) participate in the 
mechanism of aminoglycoside ototoxicity. This process is similar to that seen in 
cisplatin ototoxicity and is described in full below. 
 
1.4 Mode of Ototoxicity 
Apoptosis (programmed cell death) is a normal physiological event. The correct cell 
density is achieved and maintained by carefully controlled levels of generation and 
degeneration of cells. Whether a specific cell lives or dies therefore depends on this 
delicate balance between the pro- and anti-apoptotic factors (Cheng, Cunningham, & 
Rubel, 2005).  A toxic insult from cisplatin can activate a cascading effect on cell 
death genes ultimately resulting in cell death. It can cause the lateral wall fibrocytes in 
the cochlea to produce TNFα, which is capable of initiating apoptosis in a variety of 
cells. This process can involve the anti- and pro- apoptosis members of the Bcl-2 and 
Bax family of proteins (Dinh, et al., 2008). These proteins constitute a critical check-
point within a common cell death pathway which determines a cell‟s susceptibility to 
apoptosis (Alam, et al., 2000).  Bax and Bcl-2 possess the ability to bind to and to 
inhibit each other (Wiren, Toombs, Semirale, & Zhang, 2006), and this preferential 
expression of one factor over the other may dictate the outcome of an affected cell 
after an insult: that is, cell survival (Bcl-2) versus apoptosis (Bax). It is thus clear that 
antioxidant defences in cochlear tissues can be depleted by cisplatin and that this 
depletion can result in an increase in reactive oxygen species. Excessive ROS 
overwhelms the antioxidant defence mechanisms and results in a calcium influx 
within the cochlear outer hair cells, which in turn activates the apoptotic pathway 
causing outer hair cell death. A similar mechanism of cisplatin ototoxicity is well 
defined by Rybak, Whitworth, Mukherjea and Ramkumar (2007) and is shown in 
(Figure 7).  
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Figure 7. Mechanisms of cisplatin-induced outer hair cell death: Cisplatin (CP) enters the 
OHCs through mechano-electrical transduction channels; CP is aquated and forms 
monohydrate complex (MHC) which is more highly reactive; CP and/or MHC activates 
NOX-3, which results in the production of reactive oxygen species (ROS); ROS, in turn, 
activate JNK; these molecules then trans-locate to the cell nucleus to activate genes involved 
in the cell death pathway; these subsequent genes trans-locate to the mitochondria, causing 
the release of cyt-c, which trigger apoptosis (Rybak, Whitworth, Mukherjea, & Ramkumar, 
2007). 
 
The generation of ROS is a normal part of homeostasis and much of the data on the 
role of ROS in tissue damage comes from cell or organ culture experiments. 
Henderson, Hu, McFadden & Zheng  (1999) warn that it could be risky to simply 
extrapolate the results from in vitro experiments to the ear because the state of 
equilibrium between ROS and the set of antioxidant molecules is complex. The 
enhancement of antioxidant levels through drug application or genetic manipulation 
has also been shown to promote hair cell survival while preserving function 
(Kawamoto, et al., 2004).  
In current cancer treatment protocols, cisplatin treatment is often re-evaluated at the 
detection of ototoxicity by switching to another less antineoplastic (and less ototoxic) 
agent such as carboplatin. However, for this ototoxicity to be detected there must be a 
comprehensive hearing monitoring programme in place. 
1.5 Ototoxicity Monitoring 
Ototoxicity monitoring consists of a comprehensive pattern of audiological 
assessments designed to detect the onset of any hearing loss resulting from the 
administration of an ototoxic agent, whether it be an industrial chemical or a 
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pharmacological treatment. According to Fausti et al. (1993), the interactions between 
ototoxicity and drug administration parameters such as dosage, duration of treatment 
and serum concentration is highly variable. A physician cannot solely rely on dosage 
or serum concentrations to predict the risk of ototoxicity.  Therefore, all baseline 
testing should ideally be performed prior to any ototoxic drug administration as this 
will allow the physician the opportunity to balance the merits of a stronger dose or 
alternative treatments before hearing loss progresses into the speech range. However, 
the lack of evidence of ototoxicity can justify prolonged and more aggressive 
treatment, which could ultimately lead to a better outcome for patients treated with 
ototoxic drugs. Through close monitoring, changes in hearing thresholds can forewarn 
the Audiologist and patient to the potential need for early amplification assistance. 
 
Until very recently, ototoxicity could only be monitored by conventional pure tone 
audiometry (PTA). Although ototoxicity can be monitored through a high frequency 
tone-burst auditory brain stem response (ABR), this test is lengthy, could lack 
frequency specificity and response interpretation at ultra high frequencies is variable 
and subjective (Campbell, 2007).  Although a study done by Stavroulaki et al. (1999) 
proved that conventional audiometry normally detects hearing loss at a late, 
irreversible stage, a study done in the same year by Fausti et al. (1999) in the same 
year showed that identifying and testing a small range of frequencies, provides 
sensitive early detection to Audiologists. Adding to this argument, a study by 
Vaughan et al. (2002) demonstrated that an uppermost target frequency for a limited 
frequency range can be determined for each individual patient with a rapid and 
efficient protocol. These authors also propose that the use of smaller frequency 
increments could provide increased sensitivity for early detection of hearing loss 
within the speech range that are not usually included in routine clinical threshold 
testing. 
 
Two large American bodies for Audiologists are the American Speech-Language-
Hearing Association (ASHA) and the American Academy of Audiology (AAA). In 
1994 ASHA formed an Ad Hoc Committee on Audiologic Management of 
Individuals Receiving Ototoxic and/or Vestibulo-toxic Drug Therapy. Consequently, 
the “Guidelines for the audiologic management of individuals receiving cochleo-toxic 
drug therapy” was developed (ASHA, 1994). The AAA compiled a task force 
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consisting of seven well respected professionals who developed the AAA‟s Position 
Statement and Clinical Practice Guidelines on Ototoxicity Monitoring (AAA, 2009). 
Both of these guidelines and principles are outlined and discussed below. 
 
1.5.1 ASHA 
The American Speech-Language-Hearing Association outlines six basic principles of 
a cochleo-toxic monitoring program: 1) Specific criteria for identification of toxicity, 
2) Timely identification of at-risk patients, 3) Pre-treatment counselling regarding 
potential cochleo-toxic effects, 4) Valid baseline measures (pre-treatment/early in 
treatment), 5) Monitoring evaluations at sufficient intervals to document progression 
of hearing loss or fluctuation insensitivity, and 6) Follow-up evaluations to determine 
post-treatment effects. 
1) Specific criteria for identification of toxicity 
Subsequent changes in hearing thresholds are always compared relative to 
baseline results. ASHA criteria indicating ototoxicity induced hearing loss 
is set as: a) ≥ 20 dB decrease at any one test frequency, b) ≥ 10 dB 
decrease at any two adjacent test frequencies, or a c) loss of response at 
three consecutive test frequencies where responses were previously 
obtained. These changes must be confirmed at a follow-up appointment. 
 
2) Timely identification of at-risk patients 
Any patients, who are treated with a therapeutic drug known or suspected 
to have a cochleo-toxic side effect, require monitoring. Risk factors for 
hearing loss are summarized in Table 3 (Li, et al., 2004; Mehl & 
Thomson, 1998). A monitoring program should be implemented as soon as 
such a patient has been identified. Accurate and timely identification 
requires access to a registry of all patients receiving potentially ototoxic 
medication, and open communication between all medical personnel 
involved in treated and caring for these patients.    
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Table 3. Risk factors for hearing loss. 
 
Risk factors for congenital hearing 
loss 
Risk factors for hearing loss in adults 
receiving ototoxic treatment 
Asphyxia 
Meningitis 
Congenital or peri-natal infections 
Anatomic defects or Stigmata 
Hyperbilirubinemia 
Family history of hearing loss 
Low birth weight 
Neonatal illnesses requiring mechanical 
ventilation 
Ototoxic medications 
Age 
    Young children 
    Older adults 
Renal insufficiency  
Intravenous bolus delivery  
Co-administration with aminoglycosides  
Increased cumulative doses 
Cranial irradiation 
Noise exposure 
Diet 
 
 
3) Pre-treatment counselling regarding potential cochleo-toxic effects 
It is proposed that the physician should counsel patients regarding the 
potential effects of the ototoxic drugs, the risks and the benefits the drug 
therapy may have. The Audiologist should counsel the patient on signs and 
symptoms of hearing loss and the potential effects it may have on 
communication. Furthermore, patients should be aware of symptoms such 
as tinnitus, fullness, loss of balance or any changes in hearing sensitivity 
and they should be encouraged to inform their medical team and 
Audiologist if and when they occur. The possible synergistic effects of 
noise and ototoxicity should be stressed to those patients who work or live 
in an environment with excessive noise levels. 
 
4) Valid baseline measures 
As baseline audiometry is crucial for the successful implementation of an 
ototoxicity monitoring program, it is suggested that all patients receiving 
ototoxic medication undergo accurate evaluations. Should this initial 
evaluation, for whatever reason, not be able prior to the first dose of 
ototoxic medication, it is suggested that it be carried out no later than 24 
hours after. A comprehensive assessment should include, but is not limited 
to, a comprehensive case history, a tinnitus questionnaire such as the 
Tinnitus Ototoxicity Monitoring Interview (TOMI), otoscopy, 
tympanometry, acoustic reflexes, speech discrimination measurements, 
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pure-tone audiometry, extended high frequency audiometry, bone 
conduction testing, and an objective measure such as oto-acoustic 
emissions. 
 
5) Monitoring evaluations at sufficient intervals 
Monitoring evaluations should be scheduled parallel with each subsequent 
medical appointment in order to effectively and accurately detect ototoxic 
effects. These appointments are patient specific and will vary according to 
each individual‟s type of cancer, dose of medication and frequency of 
administration. 
 
6) Follow-up 
Follow-up testing should be done at intervals appropriate to detect post-
treatment ototoxicity, or to document (unlikely) recovery. 
 
1.5.2 AAA 
It is suggested by the American Academy of Audiology Position Statement and 
Clinical Practice Guidelines: Ototoxicity Monitoring, that baseline testing be done in 
a fairly comprehensive manner, including pure-tone thresholds in both the 
conventional- and extended high frequency ranges, tympanometry, speech 
audiometry, and the testing of OAEs (AAA, 2009). The basic audiological 
assessment, extended high frequency (EHF) audiometry and otoacoustic emission 
(OAE) measurements have formed the basis for ototoxicity monitoring over the past 
ten years. Depending on clinical purpose and patient considerations, these measures 
can either be used individually or jointly. 
 
1.5.3 Extended High-frequency Audiometry 
Extended high-frequency audiometry and evoked otoacoustic emissions have been 
shown to be more sensitive to initial ototoxic damage due to greater vulnerability of 
the basal region of the cochlea (Campbell, 2003). EHF audiometry measures pure-
tone thresholds at frequencies higher than 8 kHz and can extend up to 20 kHz, 
depending on the equipment used. Cisplatin-induced ototoxicity initially affects the 
OHCs within the basal region of the cochlea where high-frequency sounds are 
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processed (Figure 8). It is therefore imperative that pure-tone audiological evaluation 
include the upper regions of hearing not usually tested in conventional audiometric 
evaluation. 
 
Figure 8. a) The auditory nerve fibres and their tonotopic array. b) Cross-section of auditory 
nerve fibres, with the "H' indicating the hook area or extreme basal aspect of the cochlea.  
c) The arrows indicate the approximate tonotopic course of auditory nerve fibres from high to 
low frequencies in this cross-section of the auditory nerve (Musiek & Baran, 2007). 
 
1.5.4 Otoacoustic Emissions 
Patient fatigue caused by illness and treatment regimes can often interfere with 
behavioural testing; potentially reduce accuracy of the data obtained. An objective 
evaluation of the cochlear outer hair cells can be measured with OAEs. Early changes 
in OAE measurements may suggest cochlear damage that could progress to hearing 
loss (Leigh-Paffenroth, Reavis, & Gordon, 2005). Transient-evoked OAEs (TEOAEs) 
and distortion product OAEs (DPOAEs) are most commonly used in the clinic.  
1.5.4.1 High frequency DPOAEs  
DPOAEs are objective, non-invasive and do not require active participation, and are 
therefore generally well tolerated by ailing patients. When stimulated by two tones f1 
and f2 (f2 > f1) of neighbouring frequencies, the outer hair cells evoke intermodulation 
vibrations due to their non-linear transmission characteristics and corresponding 
intermodulation distortion. In humans, the 2f1-f2 DPOAE has the highest amplitude 
and is therefore primarily used for diagnosing cochlear dysfunction (Figure 9). 
DPOAEs are generated within the region of overlap of the travelling waves of the two 
primary tones close to the f2 place. The level Ldp of the 2f1-f2 DPOAE and the related 
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noise floor (average of 6 spectral lines around 2f1-f2) are measures for determining 
DPOAE amplitude and signal-to-noise ratio.  
 
 
 
Figure 9. Illustration of the measurement of distortion product otoacoustic emissions 
(DPOAEs) showing a probe assembly that fits into the external ear canal, the delivery of the 
signals to the ear via the middle ear, the generation of OAEs by outer hair cells in the cochlea 
and, finally, propagation of OAE energy as sound into the external ear canal (Anuradha 
Bantwal) (MAICO). 
 
In a study by Knight et al. (2007) it was found that EHF audiometry usually detected 
ototoxicity prior to its detection through DPOAEs, although both EHF audiometry 
and DPOAE thresholds changed prior to thresholds measured in conventional 
audiometry. However, DPOAEs are still considered a useful tool as it is time efficient 
and does not require a behavioural response from the patient.  
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According to Gorga et al. (1995) changes in outer hair cell function are seen as 
decreases in DPOAE amplitudes, decreases in the signal-to-noise ratio of the 
response, and/or a loss of DPOAEs, specific to regions of outer hair cell damage.  
There are several advantages for using DPOAEs over TEOAEs. Firstly it is suggested 
that DPOAEs may detect ototoxicity earlier than TEOAEs (Lonsbury-Martin & 
Martin, 2001), possibly because the former can more reliably be measured at higher 
frequencies where ototoxicity is first noticed. Secondly DPOAEs can be used to 
indicate the degree and configuration of the hearing loss if that data cannot be 
obtained from behavioural testing. Thirdly it has been found that a reduction in EHF 
audiometry coincides with a DPOAE reduction at around 8 kHz and below. Lastly 
DPOAEs can often be recorded more reliably in the presence of more severe SNHL 
than TEOAEs.  
There is currently no universally accepted criterion for ototoxic change in DPOAEs. 
Finding an objective method for early detection and follow-up of hearing loss has 
been a priority of researchers for a long time (Biro, et al., 2006). Such a method 
would enable clinicians to make rational decisions regarding the modification of 
treatment protocols with cisplatin. 
 
1.5.5 Tinnitus Monitoring 
According to  Seligman (1996), tinnitus is a common side effect of many ototoxic 
drugs, particularly cisplatin. When monitoring for ototoxicity, it has been suggested 
by the American Academy of Audiology‟s Position Statement and Clinical Practice 
Guidelines for Ototoxicity Monitoring (1999) that systematic questioning about 
tinnitus symptoms be done at each appointment. Tinnitus assessment methods are not 
often reported, and are mostly analyzed by patient self-report. The Tinnitus 
Ototoxicity Monitoring Interview (TOMI) (Table 4) is a useful tool in establishing 
the onset and any perceptual changes that occur during ototoxicity monitoring. Given 
the population of patients treated for cancer it can be expected that the life-threatening 
illness may overbear tinnitus self-report as these patients may be overwhelmed and 
consumed with other issues.  
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Table 4. The Ototoxicity Monitoring Interview (Campbell, 2007).  
 
1. [Clinician at the first visit] Did you 
have persistent tinnitus before the 
start of treatment? 
 No  Yes 
1a. If yes, how long have you had 
tinnitus? 
 Less than 
1 year 
 1-2 years  3-5 years 
  6-10 years 
 11-20 
years 
 More than 
20 years 
  Not sure  
 
 
 
2. Have you noticed any persistent 
tinnitus since you started the 
treatment? 
 No  Yes 
 
If no, the interview is complete. No further 
questions are required. 
 If Yes, continue to question 3. 
3. What does your tinnitus sound 
like? (Mark all that apply) 
 
Ringing 
 
Hissing 
 
Buzzing 
 
Sizzling 
 
 
Crickets 
 
Whistle 
 Hum  
  Other: 
4. Does your tinnitus have a pulsing 
quality to it? 
 No  Yes 
5. Where is your tinnitus located?  Left ear only  Right ear only 
  Both ears  Inside head 
  Other: 
6. Is your tinnitus louder on one side 
of your head than the other? 
 Right is louder 
than left 
 
 
 Left is louder than 
right 
 Equal 
7. How loud is your tinnitus on 
average? 
 Not loud 
at all 
 Slightly 
loud 
 
Moderately 
loud 
  Very loud 
 Extremely 
loud 
 
8. How much of the time do you 
think your tinnitus is present? 
 Occasionally  Some of the time 
  Most of the time  Always 
9. On average, how much of a 
problem is your tinnitus? 
 Not a 
problem 
 Slight 
problem 
 Moderate 
problem 
 
 Big 
problem 
 Very big 
problem 
 
[Clinician: Ask the following questions only if the patient (1) had tinnitus before the 
start of treatment, or (2) reported tinnitus previously with this TOMI. The objective is 
to determine if the patient‟s tinnitus is being affected by the drug treatment. If the 
patient has previously responded to this interview, each response should reflect the 
period of time since the last interview. Otherwise, each response reflects the period of 
time since before the start of treatment. 
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10. Has the sound of your tinnitus 
changed? 
 No  Yes  Not sure 
 If yes, how is it different? 
11. Has the location of your tinnitus 
changed? 
 No  Yes  Not sure 
 If yes, how is it different? 
12. Has the loudness of your tinnitus 
changed? 
 No  Yes, louder now 
  Yes, quieter now  Not sure 
13. Has the amount of time your 
tinnitus is present changed? 
 No  Yes, more often 
  Yes, less often  Not sure 
 
1.6 The New Zealand health system 
The New Zealand health system is divided into twenty semi-autonomous district 
health boards (DHBs), with Southern DHB divided into two constituencies namely 
Otago and Southland (Table 5). These DHBs have existed since 1 January 2001 when 
the New Zealand Public Health and Disability Act 2000 came into force, and are 
responsible for providing, or funding the provision of health and disability services in 
their district. The statutory objectives of DHBs include: improving, promoting and 
protecting the health of communities, promoting the integration of health services, 
especially primary and secondary care services, and promoting effective care or 
support of those in need of personal health services or disability support. 
Table 5. District Health Boards in New Zealand. 
 
District Health Boards - North-Island District Health Boards - South-
Island 
1. Northland DHB (Whangerei) 
2. Waitemata DHB (Auckland) 
3. Auckland DHB 
4. Counties Manukau DHB 
5. Waikato DHB (Hamilton) 
6. Lakes DHB (Taupo) 
7. Bay of Plenty DHB (Tauranga) 
8. Tairawhiti DHB (Gisborne) 
9. Taranaki DHB (New Plymouth) 
10. Hawke‟s Bay DHB (Napier)  
11. Whanganui DHB 
12. MidCentral DHB (Palmerston 
North) 
13. Hutt DHB (Wellington) 
14. Capital and Coast DHB 
(Wellington) 
15. Wairarapa DHB (Masterton) 
16. Nelson Marlborough DHB 
17. West Coast DHB (Greymouth)  
18. Canterbury DHB 
(Christchurch) 
19. South Canterbury DHB 
(Timaru) 
20. Southern DHB:  
            Divided into two 
            constituencies, 
            Otago (Dunedin) and 
            Southland (Invercargill)  
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Figure 10. District Health Boards in New Zealand  
(Retrieved from: http://www.moh.govt.nz/moh.nsf). 
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The population served by each DHB is shown in (Figure 11) and is based on numbers 
by Statistics NZ Population Projections of September 2007. Waitemata (North-
Auckland) and Canterbury is shown to serve the largest populations, followed by 
Auckland (Central), and Counties Manukau.   
 
Figure 11. Populations served by each District Health Board in New Zealand. 
 
A recent study by Alchin (2010) found that 7 of 23 individuals (30.4%) receiving 
ototoxic treatment in one DHB in New Zealand did not have and audiological 
assessment prior to beginning their treatment.  Furthermore the author found that 87% 
(20 of participants) had extended high frequency audiometry included in the test 
battery, but none of the baseline assessments included OAEs, acoustic reflexes or 
speech audiometry.  Of the number of participants who did receive a baseline 
audiometric evaluation, 31% did not have any other follow-up assessments during or 
after cisplatin therapy. The results of this study thus strongly indicate a lack of 
stringency in ototoxicity monitoring. The governing body for practicing Audiologists 
in New Zealand (NZAS) does not currently have any standards of practice for 
ototoxicity monitoring. The main aim of this study was to establish the current state of 
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ototoxicity monitoring in the twenty district health boards across New Zealand, via 
telephonic interview. 
1.7 Telephonic Interviewing using Questionnaires 
The telephone has enabled researchers to play a vital role in public health research 
and practice for many years (Kempf & Remington, 2007). Participation in telephone 
surveys is not only critical for examining cross-sectional characteristics of populations 
subgroups and for tracking trends and risk behaviours over time, but also to identify 
risk factors associated with multiple health conditions, and for the assessment of the 
effects of interventions. The primary purpose of telephone surveys is to make valid 
and reliable conclusions about populations that can be generalized on the basis of the 
answers of sampled respondents. However, the many challenges that can hamper data 
collection are listed in Table 6.  
 
Table 6. Continuing and emerging challenges for telephone survey research (Kempf & 
Remington, 2007). 
 
Ongoing challenges New and emerging challenges 
Selecting participants 
 
Sampling 
Telephone coverage 
Response rates 
Participation rates 
Call scheduling 
 
Cell phone sampling 
Number portability 
Answering machines 
Caller Identification (ID) 
Privacy managers and call blocking 
Collecting information 
 
Reliable and valid responses 
Mode effects 
 
Privacy and confidentiality 
Respondent burden 
 
As this study was concerned with a distinct set of known individuals, most of the 
participant selection challenges did not apply.  
1.5 Statement of the problem 
To summarize, ototoxicity is defined as the tendency of certain therapeutic agents to 
cause functional impairment and cellular degeneration of the inner ear and the eighth 
cranial nerve. Numerous pharmacologic agents have been shown to have toxic effects 
to the cochleo-vestibular system. One such drug is the platinum-based antineoplastic 
agent, cisplatin. Cisplatin is one of the most potent cytotoxic drugs currently available 
to treat different types of cancer. The clinical efficacy of cisplatin is however limited 
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by its severe ototoxicity. Ototoxicity monitoring consists of a comprehensive pattern 
of audiological assessments designed to detect the onset of any hearing loss. Three 
main methods have emerged over the past decade, and include the basic audiological 
assessment, extended high frequency (EHF) audiometry, and otoacoustic emission 
(OAE) measurement.  These measures can be used separately or in combination, 
depending on clinical purpose and patient considerations.  It is suggested by the 
American Academy of Audiology Position Statement and Clinical Practice 
Guidelines: Ototoxicity Monitoring, that baseline testing be done in a fairly 
comprehensive manner, including pure-tone thresholds in both the conventional- and 
extended high frequency ranges, tympanometry, speech audiometry, and the testing of 
OAEs (AAA, 2009).  However, New Zealand Audiologists do not currently follow a 
national ototoxicity monitoring protocol. It is therefore the author‟s hope that this 
current study will form the basis for the development of a national protocol which can 
readily be adapted by all practising Audiologists within New Zealand. 
1.6 Hypothesis and Research Question 
Since no formal protocols or best practise guidelines are available through the New 
Zealand Audiological Society, it is hypothesized that Senior/Charge Audiologists 
working within the public health sector within New Zealand are not conducting 
uniform monitoring procedures with regards to ototoxicity monitoring. 
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2 Method  
2.1 Participants 
Charge/senior Audiologists from 16 of the 20 District Health Boards in New Zealand 
were interviewed via telephone. The remaining four District Health Boards reported 
that they did not conduct ototoxicity monitoring and instead referred their patients to 
the bigger centers for monitoring.  
 
The contact details for all participants were collected from the New Zealand Ministry 
of Health website (http://www.moh.govt.nz/moh.nsf/indexmh/contact-us-dhb).  
 
Participants were included in this study if they were a Senior/Charge Audiologist 
employed by one of New Zealand‟s District Health Boards and conducted ototoxicity 
monitoring at their Audiology Department.
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2.2 Materials 
2.2.1 Interview Questionnaire 
Participants were questioned on a range of topics, including their prior knowledge of 
ototoxicity and the ototoxicity monitoring procedures for first and subsequent 
appointments currently in place at their place of employment. They were also asked to 
suggest ways in which the present system could be improved.  Because the 
questionnaire sought to obtain information regarding the perceptions of Audiologists 
on the ototoxic effects of cisplatin therapy, both open- and close ended questions were 
used. The questionnaire was developed by the author and Dr. Greg O‟Beirne, senior 
lecturer in Audiology at the University of Canterbury with input from Dr. Rebecca 
Kelly, also from the University of Canterbury. 
 
2.3 Procedures 
Once ethical approval was obtained (Appendix A) the researcher started the data 
collection phase by randomly phoning participants at different times during weekdays.  
Data collection occurred over a two week period from 18 to 29 October 2010. If a 
participant agreed to be interviewed on first contact, the interview was conducted 
immediately. The researcher only had to re-book a more suitable interview time for 
three of the participants.  Sixteen out of a possible 16 participants agreed to partake in 
this study, giving a response rate of 100%. No monetary incentive was offered.   
Interviews lasted approximately 45 minutes each, and data was gathered by directly 
transcribing onto the questionnaire. During data collection, the answered 
questionnaires were kept in a lock-up file cabinet owned by the researcher. All 
identifiable data gathered was destroyed on completion of this study. 
 
2.4 Statistical Methods  
Due to a small sample size of 16, detailed statistical analysis of data was not 
appropriate. The focus of this study was to determine the subjective views and 
opinions of charge Audiologists who are currently conducting ototoxicity monitoring 
in New Zealand. Descriptive statistics and content analysis were utilized to analyze 
the information obtained from this study. The goal of descriptive statistics was to 
provide a summary measure of some characteristic of the sample data (Blanche, 
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Durrheim, & Painter, 2008). Data were subjected to thematic analysis which was used 
to obtain reappearing themes (Holstein & Gubrium, 2003). Common themes were 
highlighted and grouped to establish major themes.  
2.5 Ethical Considerations 
Ethical approval from the Human Ethics Committee (Ref: HEC 2010/77/LR) was 
granted on October 15
th
, 2010 (Appendix A). Verbal consent was obtained from each 
participant prior to conducting the telephonic interview, and participant 
confidentiality was maintained in accordance with the conditions of ethical approval 
from the above-mentioned ethics committee. 
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3 Results 
The qualitative data is presented in the order that the Telephone Interview 
Questionnaire was conducted with the 16 participants interviewed for this study. A 
copy of the questionnaires is provided in Appendix B. Where numerical values are 
summarised, results are given as the mean ± standard deviation. 
3.1 Demographics (Questions 1 – 10) 
1. What is the name of the District Health Board (DHB) where you spend  
          most/all of your time? 
Sixteen charge Audiologists representing 16 out of the 20 DHBs in New Zealand took 
part in this study, and is listed in Table 7 below. 
 
Table 7. Sixteen District Health Boards represented in this study. 
District Health Boards - North-Island District Health Boards - South-Island 
1. Northland DHB (Whangerei) 
2. Waitemata DHB (Auckland) 
3. Auckland DHB 
4. Counties Manukau DHB 
5. Waikato DHB (Hamilton) 
6. Lakes DHB (Taupo) 
7. Bay of Plenty DHB (Tauranga) 
8. Tairawhiti DHB (Gisborne) 
9. Taranaki DHB (New Plymouth) 
10. Hawke‟s Bay DHB (Napier)  
11. MidCentral DHB (Palmerston 
North) 
12. Capital and Coast DHB 
(Wellington) 
13. Nelson Marlborough DHB 
14. Canterbury DHB (Christchurch) 
15. South Canterbury DHB (Timaru) 
16. Southern DHB:  
            Divided into two constituencies, 
            Otago (Dunedin) and 
            Southland (Invercargill)  
 
 
The four DHBs not included in this study are shown in Table 8 below. 
 
Table 8. Four District Health Boards not included in this study. 
District Health Boards - North-Island District Health Boards - South-Island 
17. Whanganui DHB 
18. Hutt DHB (Wellington) 
19. Wairarapa DHB (Masterton) 
20. West Coast DHB (Greymouth)  
  
 
 
 
2. Do you work at other DHBs or satellite clinics? 
None of the 16 participants worked at other DHBs or satellite clinics. 
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3. How long have you been working as an Audiologist?  
Work experience for participants interviewed ranged from 1 year to 36 years (mean: 
16.4 ± 10.6).  
 
 
4. Where did you obtain your qualification?  
Due to the small number of participants who agreed to partake in this study and 
privacy regulations the data for this question will not be included in the results 
section. 
 
 
5. When did you graduate?  
The participants interviewed graduated between 1977 and 2009 (mean: 1993.6 ± 
10.2). 
 
 
6. How long have you worked in your current position? 
Work experience in their current position as Charge Audiologist at a DHB ranged 
from 1 year to 23 years (mean: 7.7 ± 7.6) for all participants in this study.  
 
 
7. How long have you worked in the NZ hospital system?  
The 16 participants had varied work experience in the NZ hospital system ranging 
from 1 year to 36 years (mean: 13.9 ± 10.9). 
 
 
8. Have you ever worked in hospital-based audiology overseas?  
Twelve out of the 16 participants had never worked in hospital-based audiology 
overseas.  
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9. If so, what country and for how long?  
Four of the participants had had hospital-based work experience in audiology in the 
United Kingdom (2 participants), the United Arab Emirates (1 participant) and the 
Philippines (1 participant). 
 
 
10. Where did you learn about ototoxicity monitoring?  
The source of the participants‟ knowledge of ototoxicity monitoring is shown in  
Table 9. 
Table 9. Acquisition of knowledge regarding ototoxicity monitoring. 
Knowledge acquired Number of participants out of 16 
On the job 6 
University Program 12 
Own reading 6 
Conference 2 
 
 
3.2 Prior knowledge of Ototoxicity (Questions 11 – 26) 
11. As far as you know, what medical treatments can permanently affect hearing? 
Medical treatments that can permanently affect hearing are shown in Table 10. 
Table 10. Medical treatments that can permanently affect hearing. 
Medical Treatments Number of participants out of 16 
Cisplatin 14 
Cranial radiation 2 
Carboplatin 3 
Aminoglycosides 16 
 
Other medical treatments listed by 3 participants included: 
Aspirin, heart and blood pressure medication, salicylates, loop diuretics, furosemide, 
anti-tuberculosis-, malaria- and renal medications. 
 
 
12. What percentage of patients receiving cisplatin chemotherapy do you believe  
          could develop hearing loss?  
Twelve out of the 16 participants gave a value ranging from 0% to 75%. Four 
participants did not want to guess. 
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13. What percentage of patients receiving amino-glycosides do you believe could  
          develop hearing loss?  
Twelve out of 16 participants gave a value ranging from 0% to 65%. The same four 
participants, who did not want to guess in question 12 above, did not want to guess for 
this question either. 
 
 
14. If they did develop a hearing loss from cisplatin chemotherapy, what 
          configuration would the hearing loss typically take on?  
All sixteen participants agreed that a high frequency hearing loss would develop from 
cisplatin chemotherapy. 
 
 
15. How severe is this hearing loss likely to be?  
The majority of participants were of the opinion that cisplatin induced ototoxicity 
would induce a moderate hearing loss. 
Table 11. Severity of cisplatin induced hearing loss. 
Severity  Number of participants out of 16 
Mild 2 
Moderate 10 
Moderately-Severe 3 
Severe 4 
Profound 1 
Either of the options 1 
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16. What impact do you think this hearing loss would have on their daily life? 
Ten participants were of the opinion that a moderate hearing loss caused by cisplatin 
would have a moderate impact on their daily life (Table 12). 
Table 12. The impact of hearing loss on daily life. 
Impact  Number of participants out of 16 
No impact 0 
Slight impact 1 
Moderate impact 10 
Severe 4 
* Depends if the hearing loss has spread 
into the speech frequency ranges  
(0.5 - 4 kHz) 
2 
* This option was not part of the questionnaire, but two participants volunteered this 
data as their answer. 
 
 
17. What is the likelihood of patients receiving cisplatin chemotherapy developing  
          tinnitus? 
The majority of participants recognized the fact that it is very likely for cisplatin 
chemotherapy treatment to result in Tinnitus. 
Table 13. Likelihood of cisplatin to induce Tinnitus. 
Likelihood  Number of participants out of 16 
Not likely 0 
Slight likelihood 2 
Moderate likelihood 3 
Very likely 9 
Uncertain 2 
 
 
18. In your opinion, is the tinnitus likely to be of transient or permanent nature? 
Four participants were of the opinion that cisplatin induced Tinnitus would be 
transient in nature, while 12 participants felt it would be permanent. 
 
 
19. What impact do you think the tinnitus would have on their daily life? 
Participants felt that cisplatin induced Tinnitus would have a slight to moderate 
impact on the daily lives of cancer patients. 
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Table 14. The possible impact of cisplatin induced Tinnitus. 
Impact  Number of participants out of 16 
No impact 1 
Slight impact 7 
Moderate impact 7 
Severe 1 
 
 
20. Are patients receiving cisplatin chemotherapy likely to develop balance  
          problems? 
Nine participants agreed that cisplatin chemotherapy is not likely to cause balance 
disturbances in cancer patients. 
Table 15. The possibility of balance problems being induced by cisplatin. 
Likelihood  Number of participants out of 16 
Not likely 9 
Slight likelihood 5 
Moderate likelihood 1 
Very likely 1 
 
 
21. If they do, what impact do you think the balance problems would have on  
         their daily life? 
The effect of possible balance problems in patients treated with cisplatin 
chemotherapy is shown in Table 16. 
Table 16. The possible impact of balance problems on daily life. 
Impact  Number of participants out of 16 
No impact 4 
Slight impact 3 
Moderate impact 7 
Severe 1 
It depends on the severity 1 
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22. In your opinion, what is the purpose of ototoxicity monitoring for cancer  
          patients? 
The responses obtained from the participants could be grouped into four main 
responses:  
1) Ten participants agreed that early identification of a hearing loss should be 
established by the Audiologist, with the hope that the Oncologist might alter the 
treatment protocol to prevent further hearing loss from occurring;  
2) Two participants thought that nothing could be done to prevent a hearing loss from 
occurring due to cisplatin chemotherapy;  
3) Another two participants would like to monitor hearing loss caused by 
chemotherapy should patients later on decide to lodge a claim with the Accident 
Compensation Corporation (ACC) to obtain hearing aids. These two participants 
would like to be able to distinguish the percentage of hearing loss caused by 
chemotherapy from that related to other possible causes such as a long term history of 
noise exposure; 
4) A further two participants agreed that the main reason for ototoxicity monitoring 
was to plan possible intervention for patients affected by hearing loss due to cisplatin 
chemotherapy.  
 
 
23. What benefits do you believe are there for the patient in ototoxicity   
         monitoring?  
The four main benefits in ototoxicity monitoring for the patient were:  
1) rehabilitation, 2) prevention of further hearing loss, 3) support, and 4) social 
benefits.  
Table 17. Benefits of ototoxicity monitoring to the patient. 
Benefit  Number of participants out of 16 
Rehabilitation 6 
Prevention of further hearing loss  6 
Support  3 
Social benefits  1 
 
The participants mentioned that early identification should lead to early rehabilitation. 
They also mentioned that support is offered to patients in a monitoring program as it 
gives them an understanding of their hearing loss and a point of contact for future 
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discussions regarding rehabilitation. Participants felt that reassurance is offered in the 
sense that the patient knows that the treatment they are receiving is holistic. One 
participant pointed out that early identification of a hearing loss and the 
implementation of prompt rehabilitation through amplification holds a social benefit 
for the patient.   
 
 
24. What is your knowledge of ototoxicity monitoring protocols? 
Out of the 16 participants, one participant felt that his/her knowledge of ototoxicity 
monitoring protocols was excellent. Five participants felt they had good knowledge of 
the protocols, while half (8 participants) rated their knowledge as being fair. Two said 
they had poor knowledge of ototoxicity monitoring protocols. 
 
 
25. Can you name some ototoxicity monitoring protocols? 
Out of the 16 participants 3 could name a protocol which has been developed by the 
American Speech-Language-Hearing Association (ASHA) while 1 participant was 
aware of a protocol developed by The American Academy of Audiology (AAA). One 
participant has mentioned the use of the Brock Scale for Ototoxicity monitoring. 
 
 
26. Are you aware of any NZAS ototoxicity protocols or „best practice guidelines‟  
         regarding monitoring? 
Thirteen participants were correctly unaware of the New Zealand Audiological 
Society (NZAS) having ototoxicity protocols or „best practise guidelines‟. Two 
participants thought that such protocols and/guidelines do in fact exist, and one 
participant said he/she „assumed that the NZAS would have such guidelines but 
couldn‟t say for certain.  
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3.3 First appointment (Questions 27 – 47) 
27. Can you please describe in as much detail as you can, the referral process  
          that leads to a patient receiving potentially ototoxic treatments being seen by   
          Audiology? 
The majority of the 16 participants interviewed described the referral process as 
follows with only insignificant differences amongst departments: 
Oncology refers patients to Audiology via either fax or internal mail. Appointments 
are often needed urgently/on the day or on a very short notice period. When the 
referral was made on the day, the Audiologist tries to see the patient immediately. 
With a longer notice period, Audiology makes an appointment with the patient via 
telephone or an appointment letter that is sent out in the mail. The patient then arrives 
for their first appointment. Three participants acknowledged that patients often miss 
their first baseline audiometric evaluation and only arrives for testing after the first 
dose of treatment has been administered.   
 
 
28. Are there any assurances or checks that are made to make sure the patient is  
         seen for audiological assessment before their first ototoxic treatments? 
Thirteen out of the 16 participants said that there are no assurances or checks made at 
their departments to make sure the patient is seen for audiological assessments before 
their first ototoxicity treatment. Only 3 participants mentioned that they run assurance 
checks. Two of the above mentioned participants said that their administration staff 
rings patients before the first appointment to remind them, but that they also ring 
patients who did not arrive for their baseline assessments to establish the reason 
behind their absence. The third participant mentioned that his/her hospital has a 
specialized department who phones all patients prior to their appointments to confirm 
appointment dates and times. 
 
 
29. How important is it to obtain baseline audiometric results? 
All sixteen participants were in agreement that it is very important to obtain baseline 
audiometric results. 
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30. When adult patients arrive at the audiology clinic, how informed do you think      
          they are about the risk to their hearing from their treatment? 
The level of information that participants feel cancer patients have regarding the risk 
to their hearing from their treatment is shown in Table 18 below.  
Table 18. The level of prior knowledge of risk to hearing from ototoxic treatment. 
Level of prior knowledge Number of participants out of 16 
Uniformed 2 
Slightly informed 5 
Moderately informed 7 
Well informed 1 
Uncertain 1 
 
 
31. Where do you think most patients get this information? 
Most of the participants feel that patients get his information from Oncologists  
(Table 19).  
Table 19. Patient's sources of information regarding risk to their hearing. 
Sources of information Number of participants out of 16 
ENT 1 
Oncologist 15 
Oncology nurse 2 
Audiologist 1 
 
 
32. Whose responsibility should it be to inform the patient about the potential risk  
          to their hearing? 
Out of the 16 participants interviewed the majority (14 participants) felt it should be 
the responsibility of Oncologist to inform the patient of the potential risk to their 
hearing. One participant said the responsibility should be that of the Ear-, Nose- and 
Throat (ENT) specialist and one assigned the responsibility to the audiologist. Three 
participants didn‟t identify a specific medical discipline and felt it should stay with the 
„referrer‟.  
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33. Does your Audiology department have ototoxicity monitoring protocols?  
Seven of the 16 participants have ototoxicity monitoring protocols at their 
departments while the majority of participants (9 participants) do not.  
 
 
34. Where did this list or practice come from?  
Three participants explained that their current protocol originated from their own 
research on the topic of ototoxicity monitoring, while a fourth participant followed a 
protocol that was adopted from Auckland hospital. A fifth participant couldn‟t 
identify the exact origin of their protocol and mentioned that is was a „historical 
protocol that had been there from the start‟. Participant number six adopted a protocol 
from an article that appeared in one of the “Ear and Hearing” journals of 1999. The 
last participant said that they are currently following a protocol that originated as a 
result of a clinical trial that was running at their hospital.  
 
 
35. How are these protocols circulated amongst audiologists? 
Of the 7 participants who currently have a protocol, 5 have written down copies at 
their departments while 2 have electronic copies available on the hospital intranet. 
Four of these 7 participants, however, pass the protocols on from one colleague to 
another by „word-of-mouth‟.  
 
 
36. Is it compulsory to follow it, or are they guidelines only? 
Three of the 7 participants agreed that it is compulsory to follow these ototoxicity 
monitoring protocols, while 4 participants use the protocols as guidelines only. 
 
 
37. How often are they followed? 
Of the 7 participants, 1 reported to „always‟ follow the protocols while another 
follows it only „sometimes‟. Five participants follow their protocols „most of the 
time‟. 
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38. How much time is typically allocated for a first appointment with this type of  
          patient?  
Anywhere from 15 minutes to 1 hour is allocated for first appointments. 
Table 20. Amount of time allocated for first appointments. 
Time allocated for first appointments Number of participants out of 7 
15 minutes 1 
20 minutes 1 
30 minutes 6 
45 minutes 4 
1 hour 4 
One participant mentioned that an hour appointment for obtaining baseline 
audiometry results „would be an over-kill‟. 
 
 
39. I will now name some audiometric evaluations. Can you please say “yes” if  
          you use these methods as part of your test battery? 
Some audiometric evaluations used by the participants in this study can be seen in 
Table 21. 
Table 21. Audiometric evaluations conducted at the different DHBs. 
Audiometric evaluation Number of participants out of 16 
Case history 11 
Otoscopy 15 
Tympanometry 15 
Speech audiometry 16 
Ipsi reflexes 9 
Contra reflexes 5 
Conventional audiometry 16 
High frequency audiometry 15* 
Screening TEOAEs 0 
Diagnostic TEOAEs 0 
Screening DPOAEs 0 
Diagnostic DPOAEs 9 
7 = up to 8 kHz 
1 = 5-10 kHz 
1 = up to 12 kHz 
7 = don‟t use OAEs at all. 
Tinnitus evaluations 0 
Balance evaluations 0 
Other 1 participant makes use of the “Brock 
Scale for Ototoxicity monitoring”. 
* The remaining one participant does not use high frequency audiometry because of a 
lack of normative data available for the ultra high frequencies. 
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40. I will now list some factors that might influence what you include in your  
         current test battery. Please say “yes” if it applies to your clinic. 
Five participants do ototoxicity monitoring out of 'clinical necessity', while 11 
participants follow a 'best practice' approach to monitoring. Five out of the 16 
participants are restricted by the equipment owned: 1 department doesn't own OAE 
equipment, and the other 4 participants do not have high frequency audiometers at 
their departments. Nine of the 16 participants feel they are restricted in what they can 
do because of limited time available for appointments. Two out of 16 participants are 
restricted because equipment isn't always available to use due to small office areas. 
Equipment is therefore often located in a room that is being used by another 
audiologist. Two audiologists felt they lacked both training and knowledge on the 
topic of ototoxicity monitoring. 
 
 
41. After the first set of results is obtained, are reports (by Audiology) sent to  
          anyone?  
The majority of participants (9 participants) send out a report after baseline 
audiometric results are obtained together with a copy of the results to the referrer. 
Seven participants do not send out any reports. Instead they only send a copy of the 
audiogram to the referrer.  
 
 
42. If so, who? 
Oncologists were listed by the participants as being reported back to most frequently 
during ototoxicity monitoring. 
Table 22. Professionals receiving reports on ototoxicity monitoring. 
Results and/or copy of the audiogram to: Number of participants out of 16 
ENT specialist 3 
Oncologist 13 
Include the GP 4 
Include the patient 2 
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43. How long would it typically take for this report to be sent?  
Time frames for reports to be sent out ranged from being faxed through immediately 
to a report following within 4 weeks of the initial appointment. 
 
 
44. How do you think this audiometric information is used by the referring  
          clinician?  
Two main points were highlighted by the participants. Firstly 7 of 16 participants 
didn‟t know how the information was being used, and secondly 9 of 16 participants 
were not sure if the information was being used at all by the referring clinician.  
 
 
45. Do you think it influences treatment choices/options? 
Four participants thought that the audiometric information was not used at all by the 
referring clinician while 7 participants thought that it was. Two participants were 
uncertain and another 3 said they were „hopeful‟ that it was being used to influence 
treatment choices for their patients. 
 
 
46. Who decides if the patient needs to be seen again by Audiology? 
Fourteen of the 16 participants agreed that the Oncologist decides when the patient 
needs to be seen again, while 4 said that the decision lies with the audiologist. One 
participant mentioned that Audiology will monitor the patients once they‟re on their 
caseload, and that Oncology “sometimes let patients slip through the cracks” when is 
comes to monitoring. 
  
 
47. Who decides when this appointment will take place?  
Ten participants felt that the Oncologist was in charge of the decision when the next 
appointment would take place. Six participants felt that the decision remained with 
Audiology.  
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3.4 Subsequent appointments (Questions 48 – 51) 
48. What is done differently on subsequent assessments (if anything)  
          compared to the first? How long is this appointment typically? 
Only 3 participants conduct a shorter case history on subsequent appointments. One 
participant won‟t repeat reflexes and OAEs unless a change in hearing has been noted. 
Four participants won‟t repeat bone conduction audiometry if air conduction 
thresholds remained stable and 2 participants won‟t repeat tympanometry on 
subsequent appointments. Six participants reported that nothing changes and that they 
conduct the same protocol on subsequent appointments than they did on the initial 
appointment. 
 
 
49. Is the file updated with (or without) a new report on subsequent  
          evaluations? 
On subsequent appointments 6 participants update the file with a report while 3 
departments only fax an audiogram through to the referrer, leaving 7 departments with 
no written updates of subsequent appointments.  
 
 
50. Who decides when ototoxicity monitoring appointments stop? 
Eleven participants agreed that the Oncologist decides when monitoring stops.  Four 
participants mentioned that the Audiologist decides, and 1 participant mentioned that 
it is the decision of the treating physician when monitoring stops. 
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51. In your opinion, how long after treatment has stopped, should ototoxicity  
          monitoring continue? 
Varied responses were obtained from the participants as to how long monitoring 
should persist after cisplatin treatment has seized. The responses of 15 of the 
participants are shown below, while the remaining participant‟s response will be 
considered in the discussion section. 
 
Table 23. Length of time that ototoxicity monitoring should continue. 
Length of time that monitoring should 
continue: 
Number of participants out of 16 
1 month 2 
3 months 3 
6 months 2 
12 months 4 
2 years 1 
1, 3, 6 and 12 months 1 
Uncertain 2 
 
3.5 Improvements and recommendations (Questions 52 – 63) 
52. Do you think anything needs to be done at your DHB to improve ototoxicity  
          monitoring practice or hearing and balance outcomes for patients receiving    
          potentially ototoxic treatments? 
Thirteen participants agreed that ototoxicity monitoring can be improved at their 
DHB. Three participants didn‟t think there was much they could change to improve 
their services. 
 
 
53. What suggestions do you have? 
Participants listed the following suggestions: 
1. that a standardized protocol be made available to follow, 
2. better communication between Oncology and Audiology,  
3. more staff to be employed by the DHBs so that especially the bi-weekly 
follow-up appointments of these patients are possible for audiologists who are  
currently understaffed, 
4. balance evaluations could be included in the protocols,  
5. more awareness of where protocols are kept in audiology departments,  
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6. up-skilling of Oncologists, to stress the importance of monitoring,  
7. to possibly train administration staff to use a "priority" sticker system to point 
out important appointments such as those needed for ototoxicity monitoring, 
and especially those needed for baseline audiological assessment. 
 
 
54. What would you like to see happen? 
Participants would like to see a national protocol, based on peer reviewed research, to 
be developed. They furthermore requested an NZAS protocol or „best practise 
guidelines‟ for ototoxicity monitoring. Some participants acknowledged the need for 
high frequency audiometry equipment for them to conduct ototoxicity monitoring at 
their departments. One participant pointed out the medical staff should be better 
informed about drug interactions and its effect on hearing. Staff must be better 
informed on the importance of monitoring patients in treatment. There has to be better 
communication between departments and staff – both on an inter- and intra- 
departmental level. Another participant called for more stringent regulation to make 
sure that patients receiving ototoxic treatment do not fall through the cracks. 
Participants pointed out the need for more staff to be employed to help cope with their 
workload. 
 
 
55. Is there a need for greater instruction / awareness among audiologists?  
Fourteen out of 16 participants agreed that there should be greater instruction / 
awareness regarding monitoring among audiologists. Two participants did not agree.  
Twelve participants would like to have more training at university while 7 would like 
to get more training on the job. Eight participants would like to see more workshops 
on the topic of ototoxicity monitoring offered at NZAS conferences. 
 
 
56. Among Oncologists? 
Fourteen participants thought that Oncologists need more awareness regarding 
ototoxicity monitoring. 
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57. Would you be in favour of a national ototoxicity monitoring protocol to  
          be used by all DHBs? 
All participants unanimously agreed to a national protocol to be adopted by all the 
DHBs. 
 
 
58. If there was one, would you follow it? 
All sixteen participants would follow such a protocol if there was one. Two 
participants mentioned the fact that it needs to be evidence-based and cost effective, 
i.e. not demanding too much of their time as time is so limited. 
 
 
59. Would you follow it to the letter, or would you modify it to suit your  
          clinic? 
Nine participants would follow such a protocol to the letter, while 7 would modify it 
to suit the needs of their departments. 
 
 
60. If protocol suggested an item of equipment you don‟t currently have, how  
         easy would it be for you to obtain it? 
Two participants thought it would be relatively easy to obtain equipment needed to 
conduct ototoxicity monitoring. Eight thought is would be somewhat difficult while 5 
thought it would be difficult. One participant said it would be impossible to get 
equipment regardless.  
 
 
61. Would having a national protocol make it easier for you to get that  
          equipment? 
Fifteen participants agreed that having a national protocol would help them obtain 
equipment needed for ototoxicity monitoring. The one remaining participant who 
thought it would be impossible to get equipment, also didn‟t think having a national 
protocol would help the situation. 
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62. Who, in your opinion should be involved in developing such a protocol? 
One participant mentioned that the person who takes on the task of developing a 
national protocol should be „someone who knows how to read an article and do a 
proper literature review‟. Other stakeholders included the NZAS, Oncologists, 
Audiologists, ENT specialists, Paediatricians, Pharmacists, GPs, Physiotherapists, the 
Universities of Auckland and Canterbury, the Ministry of Health, and the Medical 
Council of New Zealand. 
 
 
63. Thank you for your time. Do you have any questions or comments for me? 
One participant requested to be informed of the outcome and results of this study. 
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4 Discussion 
 
This study surveyed 16 senior/charge Audiologists employed by any of New 
Zealand‟s District Health Boards who conducted ototoxicity monitoring at their 
Audiology Department. Subjective evidence suggests that New Zealand Audiologists 
do not currently follow a nationwide ototoxicity monitoring protocol. Therefore the 
main aim of this study was to quantify the present standing of ototoxicity monitoring 
within New Zealand. 
 
For each participant a telephone interview lasting approximately 45 minutes was 
conducted. Qualitative data from the telephonic interview was collected and analysed 
in Chapter 3. The discussion will follow the order of the telephonic interview. 
 
4.1 Demographics (Questions 1 – 10) 
Sixteen Audiologists with work experience ranging from 1 year to 36 years (mean 
16.4 ± 10.6) took part in this study. The majority of participants graduated from the 
University of Auckland, New Zealand or from the University of Melbourne, 
Australia. Four participants graduated from other countries. The participants 
graduated between 1977 and 2009 (mean: 1993.6 ± 10.2) with work experience as a 
senior Audiologist ranging from 1 year to 23 years (mean: 7.7 ± 7.6). Four of the 
participants have had hospital-based work experience overseas including countries 
such as the United Kingdom, the United Arab Emirates and the Philippines.  
 
There was no significant relationship between the date of graduation and self-reported 
knowledge of ototoxicity. The majority of participants (12) reported that they have 
acquired their knowledge on the topic of ototoxicity monitoring through the university 
program through which they graduated. No correlation however exists between the 
year in which the participants graduated and the source of their knowledge regarding 
ototoxicity monitoring. 
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4.2 Prior knowledge of Ototoxicity (Questions 11 – 26) 
The aim of this section was to obtain information regarding the perception and prior 
knowledge of Audiologists with regards to the incidence, patho-physiology and 
impact of the ototoxic effects of cancer chemotherapy. Audiologists were also 
questioned on their knowledge regarding the purpose and benefits of a monitoring 
program and whether they were aware of the existence of such protocols. 
 
Fourteen and 16 participants respectively, correctly identified cisplatin and 
aminoglycosides as the foremost medical treatments that can permanently affect 
hearing. Twelve out of the 16 participants believed that 0% - 75% of patients who 
receive cisplatin chemotherapy could develop a hearing loss which correlates fairly 
well with findings from the literature stating that 3% - 100% of patients are likely to 
sustain permanent damage to their hearing (McKeage, 1995).  These participants also 
believed that 0% - 65% of patients receiving aminoglycoside treatment could develop 
a hearing loss, when in fact the estimates from research studies are far less stating that 
only 15% - 20% of patients will suffer damage to their hearing as a result of this 
group of antibiotic treatments (Taleb, et al., 2009). All of the participants agreed that a 
high frequency loss would develop from cisplatin chemotherapy with 10 participants 
stating that this hearing loss would be moderate in severity. Research however states 
that the hearing loss is dose related, cumulative, bilateral, and usually permanent 
(Roland, 2004). Ten participants thought that this moderate high frequency hearing 
loss caused by cisplatin treatment would have a moderate impact on the patients‟ daily 
life, with only 4 participants acknowledging the fact that hearing loss could 
potentially have a severe impact on one‟s life.  Two participants mentioned that the 
severity of the hearing loss is largely dependent on whether the loss had spread into 
the speech frequency ranges of 0.5 kHz to 4 kHz.  In a study by Fausti et al. (2005), 
the effect of hearing loss on activities of daily life is well described. Fausti et al. 
(2005) argues that when hearing is impaired to the extent that it affects speech 
intelligibility, it can restrict employment and recreational and social activities. 
Hearing loss not only compromises an individual‟s safety by hindering appropriate 
responses to warning signals and alarms, but it also contributes to psychosocial and 
physical health problems resulting in job and revenue loss, depression and social 
isolation (Mulrow, et al., 1990).  
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The majority of participants (9) correctly identified cisplatin to be causing permanent 
tinnitus which could potentially have a slight to moderate impact on activities of daily 
life for these patients.  Nine participants also correctly identified that cisplatin is less 
likely to be vestibulotoxic (Sergi, Ferraresi, Troiani, Paludetti, & Fetoni, 2003). 
 
When asked about what the purpose of ototoxicity monitoring for cancer patients was, 
most of the participants (10) correctly named early identification with the hope that 
the treating physician might alter the treatment protocol as a preventative measure for 
further hearing loss, as the main purpose of monitoring. In a study by Fausti et al. 
(2005) the author lists the following options the physician may consider if an ototoxic 
hearing change is identified: 1) changing the drug to one that has a reduced risk for 
ototoxicity; 2) stopping treatment; and 3) altering the drug dosage. Conversely, if no 
change in hearing is detected, the treating physician may decide to treat the patient 
more aggressively. Alarmingly, two participants believed that nothing could be done 
to prevent a cisplatin induced hearing loss from occurring. Interestingly, these two 
participants graduated within the last four to six years and listed their knowledge of 
ototoxicity monitoring to be “good”. Equally alarming was the fact that only two 
more participants acknowledged the importance of monitoring hearing loss with the 
end goal of intervention in sight. However, when prompted about the perceived 
benefits of an ototoxicity monitoring program to the patient the following points were 
raised by participants: 1) rehabilitation (6 participants); 2) prevention of further 
hearing loss (6 participants); 3) support (3 participants); and 4) social benefits (1 
participant). 
Numerous studies have described the impact of hearing loss on individuals with a 
recent study by Preminger & Meeks (2010) highlighting the fact that hearing loss 
reduces the audibility of speech which in turn disrupts the ability to communicate with 
others, reducing the overall quality of life of individuals. Furthermore hearing loss has 
also been associated with depressive symptoms, feelings of loneliness an a small 
social network (Kramer, Kapteyn, Kuik, & Deeg, 2002). Therefore, as identified by 
the participants, the prevention of further hearing loss and the offering of appropriate 
support networks by Audiologists, should hopefully lead to better outcomes for 
patients with hearing loss. The social benefits listed by one participant as a benefit of 
ototoxicity monitoring results from early identification and implementation of prompt 
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rehabilitation through amplification. This participant argued that a patient previously 
deprived from social interaction as a direct result of hearing loss, will once again have 
access to the world through restored communication.  
 
When asked about whether the participants were aware of any existing international 
ototoxicity monitoring protocols, only 3 participants listed the protocol developed by 
the American Speech-Language-Hearing Association (ASHA), while only 1 
participant could name a protocol developed by the American Academy of Audiology 
(AAA). Thirteen participants were correct in stating that no protocol or „best practise 
guidelines‟ on ototoxicity monitoring were available from the New Zealand 
Audiological Society (NZAS). The above mentioned results strongly indicate that not 
enough awareness amongst Audiologists and the topic of ototoxicity monitoring 
currently exists, and that more should be done by Audiologists themselves and/or by 
their professional governing body to raise the much needed awareness. This could be 
accomplished either through the completion of continued professional development 
papers and courses or through formal information sessions possibly presented by the 
NZAS Standards Committee at the annual audiology conference.  
 
In summary, even though it seems as if the majority of the participants who took part 
in this study are relatively well informed about the incidence, patho-physiology and 
impact of cisplatin induced hearing loss on cancer patients, not many seem to fully 
recognize the importance or benefits of monitoring such patients for hearing loss. In 
addition not many participants seem to be familiar with the existence of available 
international ototoxicity monitoring protocols.  
 
4.3 First appointment (Questions 27 – 47) 
This section sought to obtain detailed information regarding the administrative 
journey a new cancer patient embarks on when undertaking chemotherapy treatment 
in a New Zealand public hospital. Questions regarding referral routes between 
Oncology and Audiology were explored with enquiries being made on whether any 
assurance checks are made to ensure patients are seen for audiological baseline 
assessment before their first ototoxic treatments. Participants were asked about their 
subjective opinion regarding the importance of baseline testing, how informed they 
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thought patients receiving ototoxic treatments are regarding the risk to their hearing, 
where they thought the patients source their information from, and whose 
responsibility they thought it is to inform the patients of such risks. Participants were 
also asked whether their department has an ototoxicity monitoring protocol, where it 
originated from, how it is being circulated amongst staff, how often this protocol is 
being followed by audiology staff, and whether it serves as a guideline only or 
whether it is compulsory to follow at all times. Questions regarding the protocol itself 
included the estimated time allocated for a first appointment and the methods of 
evaluation included for baseline testing. Furthermore factors that could possibly 
influence what the participants included in their test battery were explored. Lastly the 
topic of report writing and the concerns surrounding it was explored. 
 
Twelve of the 16 participants interviewed described a comparable referral process 
with only insignificant differences amongst the different departments. Only 3 out of 
16 departments currently run assurance checks to make sure patients will attend 
baseline audiometric evaluations. This method of checking involves a telephone call 
from the hospital to the patient prior to their appointment to confirm appointment 
dates and times.  A simple change in the administrative process could be to obtain 
specialized “Patient Appointment Manager/Reminder” software to completely 
automate this labour-intensive and time-consuming task. By implementing such 
software, different patients can be reached through different channels. While some 
patients regularly check their emails, others are more likely to read a SMS message 
instead, while others prefer the old-style of communicating via the telephone. 
Therefore certain software packages offer different types of appointment reminders: 
via email, SMS or phone.  Hospital departments can also make arbitrary combinations 
of these three types of appointment reminders where the patient can for instance be 
reminded by email 2 days before the appointment, and then be sent a SMS message 
one day prior to the appointment, when finally the process is completed with an 
automated call on the actual day of the appointment.   All 16 participants agreed that 
baseline audiometric testing is of the utmost importance prior to starting potentially 
ototoxic treatments. However, a recent study by Alchin (2010) showed that this 
sentiment is often not implemented in practice. Alchin found that 30% of patients 
receiving ototoxic treatment in one DHB in New Zealand did not have an audiological 
assessment prior to the commencement of their treatment. This alarming statistic 
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could significantly be reduced by the implementation of the aforementioned computer 
software. This would not only reduce the seemingly large number of missed 
appointments but also consequently reduce the incidence of hearing loss amongst 
patients receiving ototoxic treatment as a direct result of their missed appointments. 
 
Three quarters of participants interviewed (12 out of 16) felt that patients were only slightly- 
to moderately informed about the possible risk to their hearing from their treatment. Fifteen of 
the participants felt that the Oncologist was the main source of available information to the 
patients. Only one participant thought that the main responsibility of informing patients about 
what effect ototoxic treatment could potentially have on their hearing lay with the ear-, nose 
and throat specialist. Because the focus of this study was to determine the subjective 
views and opinions of Audiologists currently conducting ototoxicity monitoring, more 
research needs to be conducted to obtain objective statements from the wider medical 
community as to whom the responsibility currently falls upon, and whom it should 
fall upon. Only then can steps be implemented to streamline this process. 
 
Alarmingly, 9 of the 16 departments interviewed did not presently have an ototoxicity 
monitoring protocol. The origin of the protocols followed by the remaining 7 
departments range from „adopted protocols that had always been there‟, to 
independently-researched and developed protocols. One department adopted a 
protocol from an article by Fausti et al. (1999), while another department created their 
own protocol only because the need for it arose as a direct result of a clinical trial 
currently running at the hospital. This diversity in origin confirms our initial suspicion 
of a lack of the existence, and use of a uniform and standardized monitoring protocol. 
Even though 7 departments have written copies of their protocols, 4 choose to pass the 
protocols on from one colleague to another via „word-of-mouth‟.  We can only 
speculate as to why newcomers to the field of audiology in these hospitals are not 
encouraged to refer to the available hard copies of existing protocols. In addition, only 
3 of the abovementioned 7 departments agreed that it is compulsory to follow their 
protocols, with the remaining 4 departments using it as a guideline only. 
Disappointingly, only 1 department reported „always‟ following their protocol while 
another followed it only „sometimes‟. The remaining 5 departments follow their 
ototoxicity monitoring protocol „most of the time‟. As with conducting baseline 
evaluations, the use of a universal standardized monitoring protocol is paramount in 
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the establishment of a clear association between ototoxic drug and drug-induced 
hearing loss.  In other words, for accurate associations to be made, all parties involved 
in conducting ototoxicity monitoring should ideally conduct the same test battery for 
all patients, all the time. Sadly, this does not currently seem to be the standard practise 
amongst hospital based Audiologists in New Zealand.  
 
When asked about the amount of time allocated for a first appointment with a new 
cancer patient, half of the participants interviewed (8 out of 16) reported that 45 
minutes to an hour is allocated for this type of appointment. This correlates well with 
the literature stating that it is not uncommon to spend 40 to 45 minutes procuring a 
complete baseline audiogram (Fausti, et al., 1999). One other participant was of the 
opinion that an hour appointment for obtaining detailed baseline audiometry results 
“would be an over-kill”. Unfortunately, two departments only allow 15- and 20 
minutes for baseline testing respectively. Even though the majority of participants 
reported the use of EHF audiometry, two departments offered the following as 
grounds for not including EHF audiometry in their department‟s test battery:  
 
“No we don't do it because there aren't any normative data available” 
and 
 
“No, because it gets messy having to change headphones between normal- and 
extended high frequency ranges. Also our department doesn't have the proper 
extended audiogram form to record EHF results onto.” 
 
Even though ASHA recommends the implementation of effective programs for 
ototoxicity monitoring, time and cost requirements (as stated above) may be too 
demanding for many hospitals to support such a program. To combat this dilemma, 
Fausti and colleagues (1999) proposed a test protocol that is shortened, yet sensitive, 
using a target frequency protocol. These authors found that patients receiving 
treatment with cisplatin can be monitored for hearing threshold changes at only 5 
targeted frequencies resulting in a 94% detection rate compared with monitoring at all 
16 conventional and high frequencies. Targeting this abbreviated individualized range 
could provide an alternative to full frequency testing, removing the time and cost 
barriers that currently seem to discourage the use of monitoring programs in New 
 51  
Zealand. However, the authors warn that even with validation of such a shortened 
procedure, it is suggested that a rapid protocol be used to identify the target-frequency 
range, with all testing then confined to the target frequencies. Full frequency baseline 
testing should still be completed and repeated if ototoxic change is noted through 
using the target-frequency protocol. 
 
Lastly, when questioned about report writing and inter-departmental communication 
between Audiology and Oncology, 9 out of the 16 departments reported that they send 
out reports containing a copy of the results to the referrer. The timeframe for these 
reports vary from being faxed through immediately to arriving within 4 weeks of 
initial contact with the patient. Seven departments only forward a copy of the 
audiogram without an accompanying letter to the referrer, usually the Oncologist. 
Very rarely is the general practitioner, patient or family included in reporting back test 
results. Seven departments reported that they do not know how the test results are 
being used by the referring physician, while 9 departments doubt that it is being used 
at all. While one participant said  
 
“…they don't act on a hearing loss that's being pointed out by an Audiologist. I think 
they argue, "We either have a patient who is alive, with a hearing loss, or we have a 
dead patient"!”  
 
Another participant said  
 
“They should be comparing results, but they don't. In saying that… we don't either!”  
 
Such statements, although worrying, are especially insightful into the actual and 
current state of national ototoxicity monitoring. As pointed out by the AAA‟s position 
statement (2009), audiologic monitoring for ototoxicity is primarily performed for two 
purposes, firstly, the early detection of changes to hearing so that changes in the drug 
regimen may be considered; and secondly, so that audiological intervention can be 
implemented when handicapping hearing impairment has occurred as a result of 
ototoxic treatment. Further discussion regarding more awareness amongst both 
audiology and oncology, and better communication between the departments follows 
under section 4.5. 
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In summary, this section concludes that even though most departments reported that 
they followed a very similar referral route from oncology to audiology, many patients 
often miss their first baseline audiometric evaluation. As baseline testing forms the 
basis of interpretation of consecutive test results, it is vital that all departments 
endeavour to reduce the number of „no show‟ appointments. Such a reduction in 
missed appointments could be obtained through the installation of cost effective 
computer software at all DHBs to manage patient appointments. Furthermore, even 
though these departments reported to conduct ototoxicity monitoring, their programs 
seemed to have originated from various sources, serving very different functions, with 
only 1 department reported to having „always‟ followed their protocol as opposed to 
„sometimes‟. With only half of the participants interviewed allowing an appropriate 
40 to 45 minute timeslot for baseline testing, “available time” and “proper equipment” 
were the two main reasons presented for not being able to incorporate more tests in 
their existing test batteries. By implementing a validated 5-frequency, targeted test 
protocol Fausti et al., (1999), Audiologist could possibly alleviate the pressures of 
time constraints put on them by cutting initial baseline testing times to about one-
fourth of the usual time needed.   
 
4.4 Subsequent appointments (Questions 48 – 51) 
This part of the questionnaire sought to obtain a brief overview of how subsequent 
assessments differ from baseline testing (if at all), how long appointments typically 
last, whose decision it is to end ototoxicity monitoring and when monitoring should 
stop once treatment has stopped.  
 
Six of 16 participants reported that they conducted the same protocol they followed 
for baseline testing at subsequent appointments. Three participants only carried out a 
shortened case history with their patients while 1 department did not repeat reflex- 
and OAE testing unless a change in hearing thresholds have been noted. When 
questioned however on what criteria constitutes „a change in hearing‟, this particular 
participant was unable to present clear clinical guidelines and/or criteria. Furthermore 
it is well reported in the literature that the use of OAE testing can enable the 
Audiologist to detect significant changes in the status of auditory function much 
earlier than may be possible with conventional pure tone audiometry (Knight, et al., 
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2007). The use of OAE testing also has the added benefit of being a more attractive 
alternative to both patient and clinician as it is less time consuming to the ailing 
patient and a more cost effective clinical tool for the clinician. 
 
Also noteworthy is the fact that 4 participants would not repeat bone conduction 
testing if air conduction thresholds remained stable. Together with another 2 
participants who did not repeat tympanometry on subsequent appointments, we have 
to be somewhat critical of the level of clinical skill and how these departments assess 
and monitor conductive hearing loss in these patients. Although the assessment of 
conductive hearing loss is not the prime concern for cancer patients receiving 
potentially ototoxic treatments it certainly can not be overlooked as a possible 
conductive component can be common among infectious disease patients and in 
patients who are immuno-suppressed as a direct result of chemotherapy agents (AAA, 
2009).   
 
On subsequent appointments only 6 participants update the file with a report while 3 
departments only sent a copy of the latest audiogram to the referrer, leaving 7 of the 
16 departments without updates after subsequent appointments. This could, to a 
certain extent, explain the perceived level of inter-departmental communication 
breakdown between the departments of oncology and audiology. A possible solution 
to this problem is to adopt a system across all DHBs that seem to work well for one 
department in particular. This particular Audiology department reported to store test 
results in a database which is accessible via the hospital intranet. Thereby, all updated 
test results for a particular patient should theoretically be at the finger tips of all the 
medical disciplines involved in, and responsible for, a patient‟s care. It is conceivable 
that such a system could easily be adopted by all DHBs. 
 
When participants were asked how long after treatment had stopped they felt 
ototoxicity monitoring should continue, a varied response ranging from 1 month to 2 
years post-treatment was obtained. Worth mentioning is the response of one 
participant who pointed out that  
“We go on the basis of „give us a ring if you think your hearing has changed‟, 
because the time spent on monitoring takes time away from patients who could have 
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been fitted with hearing aids. In other words, it takes away time from the hearing aid 
waiting list, which is a far more productive usage of time.” 
Once again the underlying themes of time constraints, cost effectiveness and 
efficiency come to light. 
 
No definite criteria on how long monitoring should continue post cessation of 
treatment could be found from current literature. Two studies however appear to 
continue the monitoring process up until at least 6 months after the last dose of 
treatment (Campbell, 2007; Khoza, 2009). This result correlates well with the 
response from 7 of the 16 participants interviewed for this study. Hearing loss as a 
result of cisplatin ototoxicity has been reported to occur anywhere from shortly after 
the first dose to up to several months after treatment has stopped, with Knight et al., 
stating a median time to observation of ototoxicity as evaluated by ASHA criteria of 
135 days (2005). As with the acquisition of thorough baseline testing, adequate 
follow-up with this subset of audiology patients can not be overemphasized.  
 
In conclusion, this section highlights the following 4 points. Firstly, the lack of 
awareness amongst Audiologist to not only include the use of OAE testing in their test 
batteries but to also utilise this time- and cost-effective assessment tool in follow-up 
appointments with their patients.  Secondly, Audiologists need to be more vigilant in 
their approach to assessing and monitoring the middle-ear status of these immuno-
compromised patients. Thirdly, better inter-departmental communication could be 
obtained through implementing the storage of patient test result on hospital intra-nets 
which should then be easily accessible by all the independent medical disciplines 
involved in caring for a patient at any given time. The above mentioned system could 
ultimately lead to better patient outcomes. Lastly, even though 7 departments monitor 
their patients for late-onset hearing loss as a result of chemotherapy treatment, more 
awareness needs to be created amongst the remaining DHBs about the importance of 
continued monitoring.  
 
4.5 Improvements and recommendations (Questions 52 – 63) 
The closing section of the survey sought to obtain information regarding 
improvements and recommendations that Audiologists may have to improve the 
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current state of national ototoxicity monitoring. Participants were questioned on 
whether they thought anything could be done to improve monitoring at their own 
DHBs, what they would like to see happen on a national scale, and whether they 
thought more awareness amongst both Audiologists and Oncologists regarding 
ototoxicity monitoring was needed. Furthermore participants were asked if they would 
be in favour of a national protocol, and if such a protocol existed whether they would 
follow it or use is as a guideline only. Participants were also asked if they thought the 
existence of such a protocol would make it easier for them to obtain equipment that 
they might not currently have at their DHB. Lastly participants were asked who they 
thought should be involved in developing such a protocol.  
 
From the 13 participants who believed that improvements on their current procedures 
of ototoxicity monitoring could be made, the following key points were listed. 
Participants would like to have a standardized, national protocol, based on peer 
reviewed research, to be made available to them. Furthermore, the participants longed 
for better communication between the departments of Audiology and Oncology. 
Audiology departments generally feel understaffed and consequently incapable of 
delivering quality care to this relatively high-need group of patients.  A need to recruit 
more staff to deal with the high demand of especially bi-weekly appointments that 
some of these patients‟ care demand, currently exists. One participant would like to 
consider the inclusion of balance evaluations into their monitoring protocols, while 
another feels they could create more awareness amongst staff at their department as to 
where ototoxicity monitoring protocols are kept. Another participant feels Oncologists 
should be up-skilled on the importance of ototoxicity monitoring. Lastly, one 
department suggested that administrative staff be informed on and included in the use 
of a “priority sticker system” to visibly flag important audiology appointments such as 
those appointment slots needed for baseline- and follow-up ototoxicity monitoring 
testing.   
 
When questioned on the need for more awareness among Audiologists and 
Oncologists regarding ototoxicity monitoring, 14 of the 16 participants were in 
agreement that both disciplines would benefit from more instruction and awareness on 
the topic.  Participants unanimously agreed to the development and implementation of 
a national protocol, although interestingly only 9 departments reported that they 
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would follow such a protocol to the letter, with 7 DHBs admitting to most likely 
modifying it to suit the needs of their clinics.  One commonly identified benefit of 
implementing such a protocol was that 15 of the 16 participants agreed it would assist 
them in the acquisition of the needed equipment to conduct evaluations in accordance 
with a set national standard. 
 
Lastly, all participants agreed that numerous stakeholders be involved in the research 
and development of an ototoxicity monitoring program.  Such disciplines included the 
NZAS, Oncologists, Audiologists, ENT specialists, Paediatricians, Pharmacists, GPs, 
Physiotherapists, the Universities of Auckland and Canterbury, the Ministry of Health 
and The New Zealand Medical Council. Participants acknowledge that all of the 
aforementioned disciplines and organisations would offer invaluable contributions to 
the undertaking of researching and developing a protocol that is not only acceptable 
but also current, peer reviewed, validated and standardized, as well as time- and cost 
effective. 
 
4.6 Clinical Implications and future research 
 
The main aim of this study was to investigate the current state of ototoxicity 
monitoring across all of the 20 DHBs which form New Zealand‟s primary health care 
system. Sixteen of the 20 DHBs took part in this study with 16 charge Audiologists 
who are currently responsible for conducting ototoxicity monitoring having been 
interviewed on this topic. We hypothesized that departments do not currently follow a 
uniform monitoring protocol, but are instead following independently researched and 
developed protocols based to a large extent on the only two guidelines currently 
available - namely the guidelines proposed by the American Academy of Audiology 
(AAA, 2009) and by the American Speech-Language-Hearing Association (ASHA, 
1994). Sadly, only 7 of the 16 departments interviewed reported following a protocol 
with only 1 of these departments acknowledging AAA and ASHA as references to 
their work.  
 
An intended consequence of this study is thus to utilize the information gathered as a 
tool to create awareness amongst all disciplines involved, but specifically 
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Audiologists and Oncologist regarding the topic of ototoxicity monitoring. It is our 
hope that follow-up studies will obtain supplementary information from disciplines 
such as Oncology in order to obtain a more balanced and quantifiable analysis. 
Furthermore it is anticipated that future research will lead to the development of a 
national, peer reviewed ototoxicity monitoring protocol that would ultimately be 
accepted by all Audiologists working in New Zealand. The benefit of a universally 
accepted protocol will hopefully be reflected by better collaboration and 
communication between Audiologists and other healthcare professionals such as 
Oncologists with the ultimate benefit of better hearing outcomes for audiology 
patients receiving ototoxic treatments.  
 
4.7 Limitations of the study 
The findings of this study must be considered in light of the limitations in the 
methodology of this study and the sample of participants that were analyzed. These 
limitations will be divided into Methodological and External limitations. 
 
4.7.1 Methodological limitations: 
Method of data collection: There are a number of advantages to using a questionnaire 
to obtain data. The data gathered through using a questionnaire could be standardized 
and therefore easily analysed. Also, data can be gathered relatively quickly from a 
large number of participants. Another advantage included being able to compare 
results with similar surveys used at other research institutions. Lastly, the entire 
process could be administered with ease by a single researcher. However, making use 
of a telephone questionnaire also posed the following disadvantages. Firstly, the 
responses of participants may be inaccurate through misinterpretation of questions. To 
prevent misinterpretations from occurring, participants were constantly reminded and 
encouraged by the researcher to ask for clarification if they at any point in time felt 
unsure about the aim of any particular question. Secondly, a reasonable sample size is 
needed before responses can be used to represent the population as a whole.  As 
Audiologists are a very heterogeneous group, the small sample size of 16 participants 
is a limitation of the current study. Thirdly, although it was not the case in our study, 
the response rates can often be poor, with participants lacking the motivation to 
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complete or return questionnaires. Consequently, the researcher opted to use the 
questionnaire as a telephone interview, with a 100% response rate of 16 out of 16 
participants being interviewed.  Lastly, as this study sought to obtain subjective 
opinions from participants, qualitative- rather than quantitative data is presented, 
which may be viewed as a limitation by some.  
Self-reported data: Self-reported data is often limited by the fact that it rarely can be 
independently verified. Participant responses had to be taken at face value. Also, 
according to Heppner and colleagues (2008), self-reported data contain several 
potential sources of bias: (1) selective memory, whereby participants may or may not 
remember experiences or events that occurred at some point in the past; (2) 
telescoping, where participants may recall events that occurred at one time as if they 
occurred at another time; (3) attribution, the act of attributing positive events and 
outcomes to one's own audiology department but attributing negative events and 
outcomes to external forces; and lastly (4) exaggeration, which encompasses the act of 
representing outcomes or embellishing events as more significant than is actually the 
case. To combat these potential biased responses both open- and closed questions, 
rating scales and fixed choice questions were used in the questionnaire.  
Bias: Only the Audiologists‟ views on ototoxicity monitoring were obtained in this 
study. If time allowed, a more objective view could have been sought by including 
interviews with more healthcare professionals such as Oncologists and Paediatricians 
responsible for the care of these patients. Such data is currently being collected. 
4.7.2 External limitations: 
Time: Considerable delays were encountered with the initial research topic intended 
for this study, in a great part due to failed participant recruitment which led to a 
change of research topic in the middle of October 2010 – four months prior to the 
initial date of submission. If time allowed, a more in-depth study could have included 
a similar questionnaire directed towards Oncologists working alongside Audiologists 
in monitoring cancer patients for ototoxicity. The benefit of this would have been 
reflected in the acquisition of a less biased view on the current state of ototoxicity 
monitoring in the primary health care system of New Zealand, particularly with 
respect to the roles of Audiologists and Oncologists in the monitoring process. Further 
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disruptions to the study were caused by the Christchurch Earthquakes of September 
2010 and February 2011.  
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5 Conclusion 
 
Cisplatin-induced hearing loss is estimated to occur amongst 75% to 100% of patients 
receiving cancer treatment (McKeage, 1995). The results of a recent study by Alchin 
(2010), strongly indicated a lack of stringency in ototoxicity monitoring with only 7 
of 23 individuals (30.4%) receiving ototoxic treatment in one DHB in New Zealand 
not having undergone audiological assessment prior to the commencement of their 
treatment. Of the participants who did receive a baseline audiometric evaluation, 31% 
did not receive any follow-up assessments during or after cisplatin therapy.  
 
Results of our current study mirrored those recently found by the above mentioned 
author, with worrying evidence of 9 of 16 DHBs interviewed not presently following 
an ototoxicity monitoring protocol. Interestingly, other than initially hypothesized the 
origin of the protocols followed by the remaining 7 departments were reported to have 
ranged from historically adopted protocols to independently developed protocols. One 
department implemented an adapted version of the protocol of Fausti et al. (1999). 
This diversity in origin however, does confirm our initial suspicion of the lack of a 
uniform and standardized monitoring protocol. 
 
Now that the need for a universal ototoxicity monitoring protocol has been 
established, it is the hope of the researcher that future studies will result in the 
development of this much needed protocol and guidelines. 
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6.2 Appendix B 
Telephone Interview Questionnaire 
 
   
 
The University of Canterbury 
Department of Communication Disorders 
Telephonic Interview with Participants in Research 
The current state of ototoxicity monitoring in New Zealand 
 
 
Researcher:  Kinau VENTER, Master of Audiology Student 
   Email: kinauv@gmail.com 
   Phone: (03) 386 0306 
 
Supervisor: Dr. Greg O’BEIRNE, Senior Lecturer in Audiology 
   Email: gregory.obeirne@canterbury.ac.nz 
   Phone: (03) 364 2987 ext. 7085 
 
 
 
Introduction 
 
This interview should take approximately 30 minutes to conduct. 
 
I understand that this interview will be recorded, but only for the purpose or 
clarifying the information gathered, and that the recording will be deleted at 
the end of the study. 
 
□ Yes, I agree to participate          □ No, I do not wish to participate 
 
The purpose of this interview is twofold: 
 
 To gather accurate information about what happens when patients who 
are undergoing potentially ototoxic treatment are sent for Audiological 
testing.  
 
 To establish Audiologists‟ knowledge regarding ototoxicity monitoring. 
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Demographics 
 
1. What is the name of the District Health Board (DHB) where you spend  
 
most / all of your time _______________________________________  
 
2. Do you work at other DHBs or satellite clinics? 
□ Yes 
       Where: _______________________________________________ 
□ No 
 
3. How long have you been working as an audiologist? ______________ 
□ 0 - 2 years   □ 2 - 5 years 
□ 5 - 10 years   □ 10 years or more 
 
4. Where did you obtain your qualification? ________________________ 
 
5. When did you graduate? ____________________________________ 
 
6. How long have you worked in your current position? _______________  
□ 0 - 2 years   □ 2 - 5 years 
□ 5 - 10 years   □ 10 years or more 
 
7. How long have you worked in the NZ hospital system? _____________  
□ 0 - 2 years   □ 2 - 5 years 
□ 5 - 10 years   □ 10 years or more 
 
8. Have you ever worked in hospital-based audiology overseas?  
□ Yes 
□ No 
 
9. If so, what country and for how long? __________________________ 
 
Country __________________________________________________ 
□ 0 - 2 years   □ 2 - 5 years 
□ 5 - 10 years   □ 10 years or more 
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10. Where did you learn about ototoxicity monitoring?  
□ University programme   □ On the job 
□ Own reading – Continued Professional Development 
□ Conference 
□ Other: ________________________________________________  
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Prior knowledge of Ototoxicity 
 
11. As far as you know, what medical treatments can permanently affect  
 hearing? 
□ Cisplatin     □ Cranial radiation 
□ Carboplatin   □ Amino-glycosides 
□ Other: ________________________________________________ 
 
12. What percentage of patients receiving cisplatin chemotherapy do you  
 believe could develop hearing loss? ___________________________ 
 
13. What percentage of patients receiving aminoglycosides do you believe  
 could develop hearing loss? _________________________________ 
 
14. If they did develop a hearing loss from cisplatin chemotherapy, what 
 configuration would the hearing loss typically take on?  
□ Flat     □ Cookie Bite 
□ High Frequency   □ Low Frequency 
 
15. How severe is this hearing loss likely to be?  
□ Mild    □ Moderate 
□ Severe    □ Profound 
 
16. What impact do you think this hearing loss would have on their daily  
 life? 
□ No impact   □ Slight impact 
□ Moderate impact  □ Severe impact 
 
 
17. What is the likelihood of patients receiving cisplatin chemotherapy 
developing tinnitus? 
□ Unlikely    □ Slightly 
□ Moderately   □ Very likely 
 
 
 
 
 
18. In your opinion, is the tinnitus likely to be of transient or permanent  
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 nature? 
□ Permanent   □ Transient 
 
 
19. What impact do you think the tinnitus would have on their daily  
 life? 
□ No impact   □ Slight impact 
□ Moderate impact  □ Severe impact 
 
20. Are patients receiving cisplatin chemotherapy likely to develop balance 
problems? 
□ Unlikely    □ Slightly 
□ Moderately   □ Very likely 
 
21. If they do, what impact do you think the balance problems would have  
 on their daily life? 
□ No impact   □ Slight impact 
□ Moderate impact  □ Severe impact 
 
22. In your opinion, what is the purpose of ototoxicity monitoring for cancer  
 patients?  
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________ 
 
23. What benefits do you believe are there for the patient in ototoxicity  
 monitoring?  
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________ 
 
24. What is your knowledge of ototoxicity monitoring protocols? 
□ Excellent   □ Good 
□ Fair   □ Poor 
 
 
25. Can you name some ototoxicity monitoring protocols? 
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□ ASHA    
□ AAA 
□ Other: _______________________________________________ 
 
26. Are you aware of any NZAS ototoxicity protocols or „best practice  
guidelines‟ regarding monitoring? 
□ Yes    □ No 
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First appointment 
 
27. Can you please describe in as much detail as you can, the referral  
 process that leads to a patient receiving potentially ototoxic treatments  
 being seen by Audiology? 
E.g.: 
 Patient is seen by the oncologist and told to make an appointment themselves?  
 Oncologist makes the audiology appointment for the patient?  
 Patient is then contacted by audiology or ENT reception and appointment time is 
confirmed?  
 Patient turns up and is seen? 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
  
 
28. Are there any assurances or checks that are made to make sure the  
 patient is seen for audiological assessment before their first ototoxic  
 treatments? 
□ Yes    □ No 
 
If yes: 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
29. How important is it to obtain baseline audiometric results? 
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□ Not important   □ Somewhat 
□ Moderately    □ Very important 
 
30. When adult patients arrive at the audiology clinic, how informed do you  
 think they are about the risk to their hearing from their treatment?  
□ Uninformed   □ Slightly 
□ Moderately    □ Well informed 
 
31. Where do you think most patients get this information?  
□ ENT    □ ENT nurse 
□ Oncologist   □ Oncologist nurse 
□ Audiologist   □ Self - internet 
 
32. Whose responsibility should it be to inform the patient about the  
potential risk to their hearing? 
□ ENT     
□ Oncologist    
□ Audiologist  
□ Other: ________________________________________________
   
 
33. Does your Audiology department have ototoxicity monitoring protocols?  
□ Yes    □ No 
 
34. Where did this list or practice come from?  
 ________________________________________________________ 
 ________________________________________________________ 
 ________________________________________________________ 
 ________________________________________________________ 
 ________________________________________________________ 
 
 
 
 
 
 
 
35. How are these protocols circulated amongst audiologists?  
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□ Written down copies     
□ Passed on through „word of mouth‟ 
□ Other: ________________________________________________ 
 
36. Is it compulsory to follow it, or are they guidelines only? 
□ Yes    □ No 
 
37. How often are they followed? 
□ Never    □ Sometimes 
□ Most of the time   □ Always 
 
 
38. How much time is typically allocated for a first appointment with this  
 type of patient? ____________________________________________ 
□ 0 – 15 minutes   □ 15 – 30 minutes 
□ 30 – 45 minutes   □ 45+ minutes 
 
39. I will now name some audiometric evaluations. Can you please say  
“yes” if you use these methods as part of your test battery. 
□ Case history   □ Otoscopy 
□ Tympanometry   □ Speech Audiometry 
□ Ipsi-lateral acoustic reflexes □ Contra-lateral acoustic reflexes 
□ Conventional audiometry  □ High frequency audiometry        
      (specify the frequency)                  (specify the frequency) 
□ Screening TEOAEs  □ Diagnostic TEOAEs 
     (specify the frequency) 
□ Screening DPOAEs  □ Diagnostic DPOAEs 
     (specify the frequency) 
□ Tinnitus assessment  □ Balance assessment 
□ Other: ________________________________________________
   
 
 
40. I will now list some factors that might influence what you include in your  
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 current test battery. Please say “yes” if it applies to your clinic. 
□ Clinical necessity  □ Best practice 
□ Equipment owned by DHB  □ Available time for appointment 
□ Equipment owned but not always available (being used)  
 □ Audiologist training or knowledge 
□ Other: ________________________________________________ 
 
41. After the first set of results is obtained, are reports (by Audiology) sent 
 to anyone ?  
□ Yes    □ No 
 
42. If so, who? 
□ ENT    □ Oncologist    
□ Audiologist   □ GP  
□ Paediatrician   
□ Other: _______________________________________________ 
 
43. How long would it typically take for this report to be sent? ___________ 
□ 1 – 2 weeks   □ 2 – 3 weeks 
□ 3 – 4 weeks   □ 1 month+ 
 
44. How do you think this audiometric information is used by the referring  
 clinician?  
________________________________________________________ 
 ________________________________________________________ 
 ________________________________________________________ 
 ________________________________________________________ 
 ________________________________________________________ 
 
45. Do you think it influences treatment choices/options? 
□ Yes    □ No 
 
 
 
 
 
46. Who decides if the patient needs to be seen again by Audiology? 
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□ ENT    □ Oncologist    
□ Audiologist   □ Other: _____________________ 
 
47. Who decides when this appt will take place?  
□ ENT    □ Oncologist 
□ Audiologist   □ Other: _____________________ 
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Subsequent appointments 
 
48. What is done differently on subsequent assessments (if anything)  
 compared to the first? How long is this appointment typically? 
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________  
 
49. Is the file updated with (or without) a new report on subsequent  
 evaluations? 
□ Yes, with a report  □ No, without a report 
 
50. Who decides when ototoxicity monitoring appointments stop? 
□ ENT    □ Oncologist    
□ Audiologist   □ Other: _____________________ 
 
51. In your opinion, how long after treatment has stopped, should  
 ototoxicity monitoring continue? 
□ 1 month    □ 2 months 
□ 3 month    □ 6 months 
□ 12 month s   
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Improvements and recommendations 
 
52. Do you think anything needs to be done at your DHB to improve  
 ototoxicity monitoring practice or hearing and balance outcomes for  
 patients receiving potentially ototoxic treatments? 
 
53. What suggestions do you have? 
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________ 
 
 
54. What would you like to see happen? 
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________ 
 
 
55. Is there a need for greater instruction / awareness among audiologists?  
□ Yes    □ No 
□ More training at University □  More training on the job 
□ More workshops at NZAS conference or elsewhere  
 □ Other: ________________________________________________ 
 
56. Among oncologists? 
□ Yes    □ No 
 
57. Would you be in favour of a national ototoxicity monitoring protocol to  
 be used by all DHBs? 
□ Yes    □ No 
 
58. If there was one, would you follow it? 
□ Yes    □ No 
 
 
59. Would you follow it to the letter, or would you modify it to suit your  
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clinic? 
□ Follow it to the letter  □ Modify it to suit my clinic 
 
60. If protocol suggested an item of equipment you don‟t currently have,  
 how easy would it be for you to obtain it? 
□ Easy    □ Somewhat difficult   
□ Difficult    □ Impossible 
 
61. Would having a national protocol make it easier for you to get that  
 equipment? 
□ Yes    □ No 
 
62. Who, in your opinion should be involved in developing such a protocol? 
______________________________________________________________ 
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________
______________________________________________________________ 
 
 
63. Thank you for your time. Do you have any questions or comments for  
 me? 
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________
________________________________________________________ 
